deoxycytidine has been researched along with Bladder Cancer in 679 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (1.91) | 18.2507 |
| 2000's | 223 (32.84) | 29.6817 |
| 2010's | 318 (46.83) | 24.3611 |
| 2020's | 125 (18.41) | 2.80 |
| Authors | Studies |
|---|---|
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Black, PC; Roumiguié, M | 1 |
| Ando, R; Banno, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Nagai, T; Naiki, T; Naiki-Ito, A; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Tomiyama, N; Yasui, T | 1 |
| Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V | 2 |
| Byrski, T; Kaczmarek, K; Lemiński, A; Słojewski, M | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Gong, R; Hu, L; Li, J; Ping, Q; Qin, Y; Wang, Y; Yang, Y; Zhang, G | 1 |
| Albisinni, S; Awada, A; Barthelemy, P; Caparica, R; Carnot, A; Casert, V; Culine, S; Fantoni, JC; Gil, T; Gizzi, M; Martinez Chanza, N; Paesmans, M; Roumeguere, T; Sautois, B; Seront, E; Soukane, L; Staudacher, L; Tricard, T; Van den Brande, J; Vanhaudenarde, V | 1 |
| Anai, S; Aoki, K; Fujimoto, K; Gotoh, D; Hori, S; Ichikawa, K; Kiba, K; Maesaka, F; Matsumura, Y; Miyake, M; Mizobuchi, S; Morizawa, Y; Nakai, Y; Nishimura, N; Oda, Y; Ohmori, C; Shimizu, T; Tachibana, A; Tanaka, N; Tomizawa, M; Torimoto, K; Yoshikawa, T | 1 |
| Fan, D; Fan, Y; Fang, Z; Gao, X; Li, X; Liu, J; Yan, K | 1 |
| Kiyozuka, K; Kohei, N; Suzuki, R | 1 |
| Bao, G; Chaohong, H; Shiming, Z; Tiejun, Y; Yin, H; Yongkang, M | 1 |
| Blaheta, RA; Chun, FK; Juengel, E; Maxeiner, S; Rutz, J; Tsaur, I | 1 |
| Aggen, D; Al-Ahmadie, H; Apollo, A; Bajorin, DF; Balar, AV; Bochner, BH; Boswell, A; Cha, EK; Donahue, TF; Donat, SM; Durdin, TD; Folefac, E; Francese, K; Funt, SA; Goh, AC; Herr, HW; Hettich, G; Huang, WC; Iyer, G; Jihad, M; Kamradt, J; Khalil, M; Lash, B; Lattanzi, M; Lee, CH; McCoy, AS; McHugh, D; Mortazavi, A; Ostrovnaya, I; Pietzak, E; Quinlan, C; Ratna, N; Regazzi, A; Rosenberg, JE; Teo, MY; Truong, H; Whiting, K; Yang, Y; Zimmerman, D | 1 |
| Enokida, H; Fukumoto, W; Kawakami, I; Nakagawa, M; Okamura, S; Osako, Y; Sakaguchi, T; Sugita, S; Tamai, M; Tatarano, S; Yamada, Y; Yonemori, M; Yoshino, H | 1 |
| Jeong, BC; Kim, CK; Kim, H; Kim, R; Kwon, GY; Park, SH; Park, W; Song, W; Sung, HH | 1 |
| Allory, Y; Chevreau, C; Culine, S; Fléchon, A; Gravis, G; Guillot, A; Harter, V; Joly, F; Laguerre, B; Mahammedi, H; Pfister, C; Soulié, M | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Asano, T; Isono, M; Okubo, K; Sato, A | 2 |
| Aron, M; Brummelhuis, ISG; Chau, A; Cutie, CJ; Daneshmand, S; Keegan, KA; Maffeo, JC; Pohar, KS; Raybold, B; Reynolds, DL; Steinberg, GD; Witjes, JA | 1 |
| Laukhtina, E; Shariat, SF | 1 |
| Spek, A | 1 |
| Clark, PE; Meeks, JJ; Sexton, WJ | 1 |
| Black, PC; Contreras-Sanz, A; Eto, M; Hayashi, T; Inokuchi, J; Kang, D; Kiyokoba, R; Kohashi, K; Matsumoto, S; Matsumoto, T; Nagakawa, S; Noda, N; Oda, Y; Setoyama, D; Shiota, M; Takamatsu, D; Tsukahara, S; Uchiumi, T; Yagi, M | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Hashimoto, K; Hinotsu, S; Hotta, H; Ito, N; Kato, R; Kobayashi, K; Kunishima, Y; Maehana, T; Masumori, N; Matsukawa, M; Miyamoto, S; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Bamias, A; Caserta, C; Chang, J; Cislo, P; Climent Duran, MA; di Pietro, A; Fong, PC; Grivas, P; Kopyltsov, E; Park, SH; Parnis, FX; Powles, T; Su, PJ; Tournigand, C; Wang, J; Yamamoto, Y | 1 |
| Hirata, H; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nagao, K | 1 |
| Hori, A; Kihara, A; Nakata, M; Nihei, K; Sato, C; Shimbo, T; Yoshida, K; Yoshioka, H | 1 |
| Hu, X; Li, Y; Tong, S | 1 |
| Takahashi, T | 1 |
| Aydin, AM; Cheriyan, SK; Gilbert, SM; Hajiran, A; Jain, R; Li, R; Peyton, CC; Poch, MA; Reich, R; Sexton, WJ; Spiess, PE; Yu, A; Zemp, L; Zhang, J | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Kates, M; Rodriguez, KM | 1 |
| Shen, R; Sun, C; Tang, C; Tang, Z; Ying, X | 1 |
| Chiong, E; Kang, ET; Lim, YK; Mahendran, R; Mullapudi, SS; Neoh, KG; Ong, LT; Rahmat, JN; Wong, KY | 1 |
| Adachi, T; Azuma, H; Egawa, S; Fukuokaya, W; Fukushima, T; Hashimoto, T; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Miki, J; Mori, K; Nakamori, K; Nakamura, K; Nishimura, K; Nishio, K; Ohno, Y; Shiroki, R; Takahara, K; Tsuduki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yanagisawa, T; Yano, Y; Yoshizawa, A | 1 |
| Bao, Y; Cai, M; Chen, M; Chen, Z; Fu, C; Guo, J; Hu, H; Huang, J; Huang, Z; Jiang, S; Li, C; Su, R; Wang, Z; Wei, Q; Xue, W; Yuan, Y; Zheng, B | 1 |
| Fantinel, E; Manduca, S; Merler, S; Milella, M; Pafumi, S; Zacchi, F; Zampiva, I; Zivi, A | 1 |
| Hong, J; Hong, JY; Jeong, BC; Kim, CK; Kim, H; Kwon, GY; Park, SH; Park, W; Pyo, H; Song, W; Sung, HH | 1 |
| Blaheta, RA; Chun, FK; Cinatl, J; Grein, T; Haferkamp, A; Khadir, SE; Makhatelashvili, N; Mann, J; Maxeiner, S; Rutz, J; Sonnenburg, M; Thomas, A; Tsaur, I; Xie, H | 1 |
| Anzengruber, M; Gabor, F; Skoll, K; Szuchar, R; Wimmer, L; Wirth, M | 1 |
| Cheng, W; Chu, X; Huang, S; Zheng, H; Zheng, X; Zhou, Y | 1 |
| Cheng, HH; Dash, A; Garcia, J; Gore, JL; Holt, SK; Lam, HM; Lin, D; Makrakis, D; Montgomery, B; Mostaghel, E; Nelson, P; Porter, MP; Roudier, MP; Schade, G; Schweizer, M; Vakar-Lopez, F; Wang, Y; Winters, B; Wright, JL; Yu, EY; Zhang, X | 1 |
| O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Chan, TTW; Desai, C; di Pietro, A; Eto, M; Gao, S; Gurney, H; Lee, JL; Park, SH; Sandner, R; Su, PJ; Tsuchiya, N; Wang, J | 1 |
| Chau, A; Cutie, CJ; Dickstein, RJ; Guerrero-Ramos, F; Hafron, JM; Keegan, KA; Maffeo, JC; Messing, EM; Mir, MC; Morris, D; Palou, J; Raybold, B; Rodriguez, O; Scarpato, KR; Stromberg, KA; Tyson, MD | 1 |
| Enokida, H; Iizasa, S; Inoguchi, S; Matsushita, R; Nakagawa, M; Okamura, S; Osako, Y; Sakaguchi, T; Tamai, M; Tanimoto, A; Tatarano, S; Yamada, Y; Yokoyama, S; Yoshino, H | 1 |
| Du, C; Lin, J; Tian, Y; Wang, Z; Zhang, J; Zhang, L; Zheng, M; Zhu, Y | 1 |
| Bellmunt, J; Caserta, C; Costa, N; di Pietro, A; Grivas, P; Gupta, S; Gurney, H; Huang, B; Kalofonos, H; Laliberte, RJ; Loriot, Y; Park, SH; Petrylak, DP; Powles, T; Sridhar, SS; Sternberg, CN; Ullén, A; Valderrama, BP; Voog, E; Yamamoto, Y | 1 |
| Horenblas, S; Los, M; Reesink, DJ; van de Garde, EMW; van der Nat, PB; van Melick, HHE | 1 |
| Bloudek, L; Derleth, CL; Devine, B; Hepp, Z; Lenero, E; Lill, JS; McKay, C; Ramsey, SD; Sullivan, SD; Wright, P | 1 |
| Mellema, JJ; van der Heijden, MS; van Rhijn, BWG | 1 |
| Alva, AS; Bangs, R; Bastos, BR; Daneshmand, S; Flaig, TW; Fowles, JS; Goldkorn, A; Gustafson, DL; Lerner, SP; Lucia, MS; MacVicar, GR; McConkey, DJ; Milowsky, MI; Plets, M; Tangen, CM; Theodorescu, D; Thompson, IM | 1 |
| Small, EJ | 1 |
| Hosomi, T; Makino, Y; Otsuka, H; Shibasaki, N; Shichiri, Y; Uketa, S | 1 |
| Aeppli, S; Alborelli, I; Berthold, D; Bubendorf, L; Cathomas, R; Erdmann, A; Hadaschik, B; Hayoz, S; John, H; Kiss, B; Mach, N; Musilova, J; Özdemir, BC; Petrausch, U; Rothschild, SI; Schmid, M; Schneider, M; Spahn, M; Strebel, RT; Zihler, D | 1 |
| Achkar, BE; Bhardwaj, N; Brody, R; Cabal, R; Cetnar, JP; Chan, KG; D'Souza, A; Daneshmand, S; Dorff, TB; Ellis, E; Galsky, MD; Gnjatic, S; Gogerly-Moragoda, M; Gonzalez-Kozlova, E; Haines, GK; Horwitz, A; Ioannou, G; Izadmehr, S; Jun, T; Kelly, G; Kim-Schulze, S; Kinoshita, Y; Kyriakopoulos, C; Lewis, S; Mamtani, R; Mehrazin, R; Mouw, KW; Neil, BO; Nie, K; Nose, Y; Pal, SK; Samstein, RM; Sebra, R; Sfakianos, J; Wang, L; Xie, H; Yu, M; Zhao, Q; Zhu, J | 1 |
| Csongvai, C; Jeskó, J; Kearney, M; Macher, T; Maráz, A; Nagy, B; Tischler, E | 1 |
| Alhalabi, O; Campbell, MT; Corn, PG; Czerniak, B; Dinney, CPN; Gao, J; Goswami, S; Guo, C; Hansel, DE; Holla, V; Kamat, AM; Khandelwal, J; Kovitz, C; Lin, Y; Logothetis, C; Matin, S; Moussa, MJ; Msaouel, P; Navai, N; Pilie, P; Shah, AY; Siefker-Radtke, AO; Tannir, NM; Wilson, N; Xiao, L | 1 |
| Abrahams, D; Ali, J; Bazargan, S; Beatty, MS; Blauvelt, J; Bunch, B; Cox, C; Hall, AM; Landin, A; Ojwang', AME; Pilon-Thomas, S; Poch, M; Rejniak, KA | 1 |
| Dong, X; Hou, F; Li, C; Wang, S; Wang, Y; Zhang, M | 1 |
| Barry, E; Bivalacqua, TJ; Daniels, MJ; Kates, M; Milbar, N; Sankin, A; Schoenberg, M | 1 |
| Chen, M; Fu, G; Guan, Y; Guo, Z; Jiang, H; Jiang, X; Liang, J; Lu, T; Niu, X; Sun, R; Sun, S; Sun, X; Tang, J; Wang, H; Wang, X; Wu, K; Wu, X; Yang, C; Zheng, S; Zhong, B | 1 |
| Grimberg, DC; Inman, BA; Shah, A | 1 |
| Diao, WL; Guo, HQ; Wang, TW; Yang, R; Yuan, H; Zhao, XZ | 1 |
| Haas, CR; McKiernan, JM | 1 |
| Brooks, NA; O'Donnell, MA | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Chang, SS | 3 |
| Witjes, JA | 2 |
| Berg, M; Cinatl, J; Michaelis, M; Rothweiler, F; Stege, H; Vallo, S; Winkelmann, R | 1 |
| Abate-Shen, CT; Anderson, CB; DeCastro, GJ; Drake, CG; Holder, D; James, B; Kates, MM; Lee, SM; McKiernan, JM; Pak, JS; Sui, W; Virk, RK | 1 |
| Basch, E; Dueck, A; Johansen, C; Lindberg, H; Pappot, H; Taarnhøj, GA | 1 |
| Montgomery, RB; Ruplin, AT; Spengler, AMZ; Wright, JL | 1 |
| Bajorin, DF; Bochner, BH; Dalbagni, G; Donat, SM; Herr, HW; Iyer, G; Milowsky, MI; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Russo, P; Tully, CM; Zabor, EC | 1 |
| Peard, L; Saltzman, AF; Stark, T; Ziada, A | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Babjuk, M | 2 |
| Enokida, H; Kuroshima, K; Nakagawa, M; Nohata, N; Osako, Y; Sugita, S; Tatarano, S; Tsuruda, M; Yonemori, M; Yoshino, H | 1 |
| Donnell, R; Hong, T; Hu, Y; Pattarawat, P; Tsai, CL; Wallace, S; Wang, HR; Wang, J; Wang, TH | 1 |
| Aceti, M; Bayle, S; Duckett, D; Frydman, SM; Grant, W; McDonald, P; Monastyrskyi, A; Nieto, A; Quereda, V; Roush, WR; Sansil, SS; Teng, M; Vena, F | 1 |
| Hayama, T; Hiraki, R; Miyata, Y; Nakamura, N; Nakashima, M; Nakashima, MN; Ohyama, K; Sakai, H; Wang, M; Yasuda, T | 1 |
| Arima, K; Kanda, H; Kato, M; Kitano, G; Masui, S; Nishikawa, K; Nishikawa, T; Owa, S; Sasaki, T; Sugimura, Y; Sugino, Y; Uchida, K; Yoshio, Y | 1 |
| Ando, R; Etani, T; Hamamoto, S; Iida, K; Kawai, N; Nagai, T; Naiki, T; Nozaki, S; Sugiyama, Y; Tasaki, Y; Yasui, T | 1 |
| Cao, Z; de Vere White, R; Guo, J; Lin, TY; Long, Q; Ma, AH; Pan, CX; Sonpavde, GP; Xia, R; Zhang, H | 1 |
| Alsyouf, M; Groegler, J; Hu, B; Pierorazio, P | 1 |
| Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X | 1 |
| Chan, W; Chu, SKP; Lee, KCE; Mui, WH; Wong, CSF | 1 |
| Allory, Y; Culine, S; Fléchon, A; Gravis, G; Guy, L; Harter, V; Joly, F; Laguerre, B; Mottet, N; Pfister, C; Soulié, M | 1 |
| Barocas, DA; Bivalacqua, TJ; Black, PC; Cookson, MS; D'Andrea, D; Dall'Era, MA; Daneshmand, S; Dinney, CP; Holzbeierlein, JM; Kassouf, W; Lotan, Y; Matin, S; McGrath, JS; Morgan, TM; North, S; Petros, FG; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Wright, JL; Zargar, H | 1 |
| Hussain, SA; Riaz, IB | 1 |
| Huang, CP; Shyr, CR; Wu, CC | 1 |
| Akdogan, B; Akyol, F; Esen, CSB; Hurmuz, P; Kilickap, S; Ozen, H; Ozyigit, G | 1 |
| Chen, F; Gou, S; Wang, X | 1 |
| Buffi, N; Casale, P; Colombo, P; Contieri, R; Fasulo, V; Frego, N; Guazzoni, G; Hurle, R; Lazzeri, M; Lughezzani, G; Morenghi, E; Paciotti, M; Saita, A | 1 |
| Cho, CJ; Ho, JY; Wu, CL; Yang, CW; Yu, CP; Yu, DS | 1 |
| Cao, Y; Chu, C; Liu, Z; Lu, J; Wu, C; Zhang, Y | 1 |
| Dash, A; Diamontopoulos, LN; Gore, JL; Grivas, P; Holt, SK; Lin, DW; Nyame, YA; Psutka, SP; Schade, GR; Winters, BR; Wright, JL; Yu, EY | 1 |
| Chen, L; Ju, L; Luo, Y; Peng, T; Wang, G; Wang, X; Xiao, Y; Xiong, Y; Xu, H; Yuan, L | 1 |
| Hupe, MC; Kramer, M; Matzen, M; Merseburger, AS; Offermann, A; Perner, S; Tharun, L | 1 |
| Bai, H; Bi, X; Cao, C; Chen, Y; Feng, X; Guan, K; Guan, Y; Hu, L; Hu, Z; Jiang, W; Li, C; Li, Y; Liu, Y; Ma, J; Shi, H; Shou, J; Tian, J; Wang, D; Xiao, Z; Zhang, J; Zhang, W; Zheng, S; Zhou, A | 1 |
| Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
| Arora, S; Brown, L; Cai, EY; Corey, E; Garcia, J; Hsieh, AC; Lakely, B; Lam, HM; Lee, JK; Liu, Y; Montgomery, B; Nguyen, HM; Vakar-Lopez, F; Wong, A; Wright, JL | 1 |
| Im, HS; Jeong, H; Kim, HD; Kim, JH; Lee, JL; Park, I; Yoon, SK | 1 |
| Bau, L; Browning, RJ; Callan, JF; Folkes, L; Gray, MD; Hampson, A; Kamila, S; Kiltie, AE; McHale, AP; Ruan, JL; Stride, E; Vojnovic, B; Yildiz, YO | 1 |
| Bau, L; Browning, RJ; Callan, JF; Elliott, A; Gray, M; Kamila, S; Kiltie, AE; McHale, AP; Ruan, JL; Smart, S; Stride, E; Thompson, J; Vojnovic, B; Yildiz, YO | 1 |
| Cho, YM; Hong, B; Kim, YS; Lee, JL; Lee, Y | 1 |
| Araki, M; Edamura, K; Iwata, T; Katayama, S; Kobayashi, Y; Nasu, Y; Nishimura, S; Sadahira, T; Sako, T; Takamoto, A; Wada, K; Watanabe, M; Watanabe, T | 1 |
| Alva, A; Bandini, M; Curran, C; Diamantopoulos, LN; Gallina, A; Grivas, P; Grunewald, CM; Gupta, S; Jain, RK; Lee, JL; McGregor, BA; Mossanen, M; Necchi, A; Niegisch, G; Olson, KM; Pond, GR; Ravi, P; Singh, P; Skelton, WP; Sonpavde, GP; Su, C; Tward, JD | 1 |
| Kakehi, Y; Liu, D; Matsuoka, Y; Sugimoto, M; Taoka, R; Tohi, Y; Zhang, X | 1 |
| Dahl, E; Eschenbruch, J; Gaisa, NT; Gan, L; Kistermann, J; Knüchel, R; Noetzel, E; Rose, M; Rushrush, S | 1 |
| Atherton, PJ; Bajorin, D; Ballman, KA; Dreicer, R; Flaig, TW; Hahn, O; Halabi, S; Hoimes, C; Katragadda, S; Misleh, J; Morris, MJ; Mortazavi, A; Picus, J; Plimack, ER; Rosenberg, JE; Small, EJ; Stadler, WM; Sweeney, C; Tagawa, ST; Teply, BA; Vaena, D | 1 |
| Alimohamed, N; Eigl, BJ; Lavoie, JM; McLeod, D; North, S; Ong, M; Sridhar, SS | 1 |
| Azih, I; Escudero, DO; Ghosh, S; Hasanali, SL; Hennig, M; Hupe, MC; Jordan, AR; Kuczyk, MA; Lokeshwar, VB; Lopez, LE; Merseburger, AS; Morera, DS; Racine, RR; Sarcan, S; Terris, MK; Wang, J; Zhou, M; Zhu, H | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Curran, C; Dranitsaris, G; Kilbridge, KL; Mantia, C; McGregor, BA; Montazeri, K; Mossanen, M; Preston, MA; Ravi, P; Sonpavde, G; Steele, GS; Thomas, JD | 1 |
| Brede, CM; Broekhuizen, HT; Busman, RD; Kuipers, SK; Kuperus, JM; Lane, BR; Noyes, SL; Tobert, CM | 1 |
| Chang, YH; Huang, HS; Lu, MC; Tam, HL | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Bao, JM; Chen, MK; Chen, ZJ; Duan, HF; Guo, WB; Huang, ZP; Liang, ZJ; Liao, DY; Liu, CD; Liu, Y; Qin, ZK; Wang, HY; Wang, P; Xia, M; Xie, X; Xue, KY; Yang, C; Yang, JK; Ye, YL; Zhou, JH; Zhou, JW; Zhou, QZ | 1 |
| Ando, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Matsumoto, D; Nagai, T; Naiki, T; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Yasui, T | 1 |
| Cui, Y; Dreicer, R; Emamekhoo, H; Frankel, PH; Hoimes, C; Kim, WY; Lara, PN; Lyou, Y; Michaelson, D; Milowsky, M; Mortazavi, A; Newman, E; Pal, SK; Parikh, M; Parikh, R; Srinivas, S; Teply, B; Vaishampayan, U; Weng, P; Zhang, T | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Ando, R; Hotta, Y; Kimura, K; Kondo, M; Yasui, T | 1 |
| Böhm, R; Grünberger, B; Kraischits, N; Kudlacek, S; Kunit, T; Lamche, M; Loidl, W; Meran, JG; Niedersüss-Beke, D; Puntus, T; Schramek, P | 1 |
| Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Dong, XY; Gou, X; He, WY; Huang, XL; Lin, Y; Xie, XY; Yang, XY; Yin, HB; Zhang, H | 1 |
| Chung, JI; Hwang, H; Kim, TS; Noh, GH | 1 |
| Daste, A; Dousset, V; Gross-Goupil, M; Hoepffner, JL; Ravaud, A; Teyssonneau, D | 1 |
| da Silva, GN; Filoni, LT; Salvadori, DMF; Salvadori, MC | 1 |
| Colleselli, D; Löbig, N; Martini, T; Mitterberger, MJ; Wezel, F | 1 |
| Higashi, M; Momose, S; Morozumi, M; Tamaru, JI; Yamashita, T | 1 |
| Cui, Y; Guo, H; Huang, R; Huang, X; Lu, Q; Shen, L; Yan, J; Yang, L; Zhang, D; Zhao, X; Zheng, X; Zhuang, J | 1 |
| Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N | 1 |
| Juang, GD; Lai, HC; Wu, CK | 1 |
| Chang, JW; Chang, YH; Chuang, CK; Juan, YH; Liao, TY; Liaw, CC | 1 |
| Barone, C; Bassi, P; Cassano, A; Marandino, L; Monterisi, S; Nazzicone, G; Orlandi, A; Pierconti, F; Racioppi, M; Rossi, E; Schinzari, G | 1 |
| Begum, A; Del Carmen Rodriguez Pena, M; Dinalankara, W; Hahn, NM; Hoque, MO; Mao, S; Marchionni, L; Netto, GJ; Ooki, A; Rasheed, ZA; Sidransky, D; VandenBussche, CJ | 1 |
| Abdallah, A; Baumann, BC; Christodouleas, JP; Hwang, WT; Khaled, HM; Smith, A; William, H; Zaghloul, MS | 1 |
| Glynn, P; Price, L; Zarkar, A | 1 |
| Thoma, C | 1 |
| Bivalacqua, TJ; Black, PC; Daneshmand, S; Kassouf, W; Shah, JB; Spiess, PE; van Rhijn, BW; Zargar, H | 1 |
| Cao, Y; Dong, P; Fan, W; Guo, S; Han, H; Jiang, L; Li, X; Li, Y; Liu, Z; Qin, Z; Shi, Y; Yao, K; Ye, Y; Zhou, F | 1 |
| Borgmann, H; Cebulla, A; Dogan, S; Frank, T; Hennig, M; Hofbauer, SL; Klatte, T; Kramer, M; Merseburger, AS; Salem, J; Struck, JP | 1 |
| An, Q; Xu, N; Zhou, L | 1 |
| Abdelrheem, AM; Elnaggar, MS; Gabr, A; Mohamed, HAH; Salem, MA | 1 |
| Endo, T; Ikeda, A; Kandori, S; Kawai, K; Kojima, T; Kurobe, M; Miyagawa, T; Nishiyama, H; Tsutsumi, M; Uchida, M | 1 |
| He, W; Li, X; Tong, H; Wang, Q; Yang, X; Yin, H; Zeng, Y; Zhang, Y | 1 |
| Martínez-Piñeiro, L; Rios González, E | 1 |
| Brand, TC; Culkin, DJ; Evans, CP; Hafez, KS; Holzbeierlein, JM; Karsh, LI; Koppie, TM; Lerner, SP; Mack, PC; Messing, EM; Plets, M; Sahasrabudhe, DM; Svatek, RS; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wilson, SS; Wood, DP; Wu, G | 1 |
| Stone, L | 1 |
| Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH | 2 |
| Choudhury, A; Christodoulou, M; Henry, A; Hodgson, C; Hoskin, PJ; Kennedy, J; Reeves, KJ; Slevin, F; Zeniou, A | 1 |
| Basset, V; Cortesse, A; Culine, S; de la Taille, A; Desgrandchamps, F; Dumont, C; Gaudez, F; Masson-Lecomte, A; Meria, P; Meyer, F; Michel, C; Mongiat-Artus, P; Vordos, D | 1 |
| Baloğlu, E; Çalışkan, Ç; Erzurumlu, Y; Karavana, SY; Özdemir, Dİ; Şen, S; Şenyiğit, ZA; Sevin, G | 1 |
| Guo, P; Han, Z; Jiang, H; Peng, L; Shang, W; Tian, J; Wang, H; Wang, K; Wang, L; Xu, W | 1 |
| Cao, J; Li, S; Wang, Q; Wu, G | 1 |
| Bai, XG; Ding, M; Jin, ZL; Xu, HJ; Yang, Y; Zhang, LJ | 1 |
| Cong, X; Dong, X; Fan, J; Fang, S; Tang, Y; Wang, S; Yuan, Y | 1 |
| Hashimoto, K; Itoh, N; Maehana, T; Masumori, N; Nishiyama, N; Okabe, K; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Kim, HS; Seo, HK | 1 |
| Apolo, AB; Chowdhury, S; Galsky, MD; Hahn, NM; Merseburger, AS; Milowsky, MI; Petrylak, D; Powles, T; Quinn, DI; Rosenberg, JE; Siefker-Radtke, A; Sonpavde, G; Sternberg, CN | 1 |
| Chang, YY; Gao, YJ; Gong, YW; Guo, Q; Wang, YH; Wang, ZP; Zhang, S; Zhao, YL | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Komura, K; Minami, K; Narumi, Y; Nomi, H; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL | 1 |
| Ahmadi, N; Amini, E; Bazargani, ST; Cai, J; Clifford, TG; Daneshmand, S; Djaladat, H; Hugen, CM; Miranda, G; Sherrod, AE | 1 |
| Dabke, IR; Gao, J; Hennig, MJ; Hoy, JJ; Kallifatidis, G; Kuczyk, MA; Li, J; Lokeshwar, BL; Lokeshwar, VB; Merseburger, AS; Morera, DS; Pearce, RF; Smith, DK | 1 |
| Chen, D; Cheng, M; Gao, Q; Jiang, Y; Li, J; Li, Y; Liang, Y; Lin, S; Liu, Z; Sheng, L; Wu, M; Zhang, H; Zhang, X; Zhang, Y; Zhu, F | 1 |
| Fan, J; Jiang, JT; Liu, ZH; Mu, XY; Sun, F; Tan, MY; Wang, RJ; Wang, X; Wu, K; Yao, ZX; Zheng, JH; Zheng, Z | 1 |
| Harrison, MR; Inman, BA; Meleis, L; Moore, R | 1 |
| Li, B; Xie, D; Zhang, H | 1 |
| Maslov, DV; Matrana, M; Thomas, K | 1 |
| Fang, Z; Fu, B; Hao, P; Xu, J; Yang, Z; Zhou, L | 1 |
| van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS | 1 |
| Anai, S; Fujii, T; Fujimoto, K; Gotoh, D; Hori, S; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Ohnishi, S; Owari, T; Shimizu, T; Tanaka, N; Torimoto, K; Toritsuka, M | 1 |
| Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
| Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM | 1 |
| Johnson, DC; Pruthi, RS; Woods, ME | 1 |
| Ahn, JJ; McKiernan, JM | 1 |
| Huang, CH; Huang, CN; Lee, MH; Li, CC; Li, WM; Tsai, CC; Wu, WJ; Yeh, HC | 1 |
| Chun, F; Gontero, P; Gurioli, A; Kluth, LA; Lucca, I; Marson, F; Martorana, G; Mehnert, A; Oderda, M; Pappagallo, G; Rink, M; Sanguedolce, F; Schiavina, R; Schmid, M; Shariat, SF; Sogni, F | 1 |
| Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J | 1 |
| Gabor, F; Kählig, H; Neutsch, L; Pichl, C; Spijker, S; Wirth, EM; Wirth, M | 1 |
| Benson, M; Goldman, B; Lee, CT; Lenz, HJ; Lerner, SP; Petrylak, DP; Sakr, WA; Skinner, EC; Tangen, CM; Thompson, IM; Wilson, SS | 1 |
| Abacioglu, U; Alsan Cetin, I; Atasoy, BM; Dane, F; Ibrahimov, R; Ozgen, Z; Turhal, NS; Turkeri, L; Ucuncu Kefeli, A | 1 |
| De, D; George, J; Kanwar, AJ; Mahajan, R; Saikia, UN | 1 |
| Abe, H; Azuma, H; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Gabor, F; Kählig, H; Neutsch, L; Spijker, S; Wambacher, M; Wirth, EM; Wirth, M | 1 |
| Eroglu, Z; Fruehauf, JP | 1 |
| Bochner, BH; Chen, LY; Dalbagni, G; Donat, SM; Herr, HW; Sternberg, IA | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Kawamura, N; Matsushita, M; Nin, M; Okada, T; Tsujihata, M; Ujike, T | 1 |
| Choi, W; Jinesh G, G; Kamat, AM; Laing, NM; Lee, EK; McConkey, DJ | 1 |
| Hiratsuka, Y; Ishii, T; Matsubara, T; Taira, H | 1 |
| Bajorin, DF; Bochner, BH; Dalbagni, G; Kent, M; Kim, PH; Sfakianos, JP; Zhao, P | 1 |
| Cass, CE; El-Gehani, F; Ghosh, S; Lai, R; Mackey, JR; North, S; Santos, C | 1 |
| Eberhart, C; Goldberg, MF; Hsu, AW; Montaner, S; Sodhi, A | 1 |
| Abe, H; Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Hatakeyama, S; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Arantes-Rodrigues, R; Colaço, A; Ferreira, R; Lara Santos, L; Moreira da Silva, V; Oliveira, P; Palmeira, C; Pinto-Leite, R | 1 |
| Bellmunt, J; Blais, N; Castellano, D; Cerbone, L; Le-Guennec, S; Machiels, JP; Peters, F; Risse, ML; Skoneczna, IA; Sternberg, CN; Theodore, C; Voog, E | 1 |
| Chen, GP; Li, DC; Li, FY; Liu, Z; Wang, H; Wang, ZP; Zhao, Y | 1 |
| Azad, A; Bolton, D; Davis, ID; Eapen, R; Liew, MS; Sengupta, S; Tafreshi, A | 1 |
| Alfred Witjes, J; Arentsen, HC; Falke, J; Høgset, A; Oosterwijk, E | 1 |
| Day, KC; Day, ML; Grivas, PD; Hussain, M; Karatsinides, A; Kunju, LP; Liebert, M; Owainati, I; Paul, A; Shakir, N; Thomas, D | 1 |
| Wang, W; Wang, Y; Zhang, P; Zhang, XD | 1 |
| Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Fukawa, T; Fukumori, T; Izaki, H; Kagawa, J; Kanayama, HO; Komori, M; Oi, H; Oyama, T; Sasaki, Y; Senzaki, T; Takahashi, H; Takahashi, M; Takemura, M; Yamaguchi, K; Yamamoto, Y | 1 |
| Camargo, EA; da Silva, GN; Gobette, CP; Marcondes, JP; Salvadori, DM | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Lin, TC | 1 |
| Abu-Taleb, F; Elbolkainy, T; Farag, K; Haggag, R; Khaled, H; Shamaa, S; Zekri, AR | 1 |
| Azria, D; Culine, S; Fenoglietto, P; Pouessel, D; Rebillard, X; Riou, O; Thezenas, S; Thuret, R | 1 |
| Cury, FL; Duclos, M; Faria, SL; Kassouf, W; Souhami, L; Sturgeon, J; Turgeon, GA | 1 |
| Ahn, KO; Jeong, KC; Jung, NR; Lee, KH; Lee, SJ; Park, WS; Seo, HK; Shin, JS | 1 |
| Chen, J; Fan, L; Li, L; Li, W; Mao, L; Nai, L; Wang, J; Wen, R; Yang, C; Zheng, J | 1 |
| Guo, S; Huang, L; Kim, WY; Miao, L; Satterlee, A; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 3 |
| Dong, P; Han, H; Jiang, L; Li, Y; Liu, Z; Qin, Z; Yao, K; Yao, M; Zhang, Z; Zhou, F | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Minami, K; Narumi, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Uchimoto, T; Uehara, H; Yamamoto, K | 2 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Agarwal, N; Al-Hawary, M; Daignault, S; Dawsey, S; Day, KC; Day, ML; Eisenberger, MA; Grivas, PD; Hussain, M; Levine, EG; MacVicar, GR; Puzanov, I; Quinn, DI; Siefker-Radtke, AO; Smith, DC; Srinivas, S; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
| Badran, A; Enein, HA; Ghoneim, M; Kalawee, ME; Khaled, HM; Mahran, TZ; Manie, M; Mansur, O; Megeed, HA; Ramadan, SM; Saber, RA; Shafik, HE; Sherbini, ME; Zabhloul, MS | 1 |
| Booth, CM; Mackillop, WJ; Peng, Y; Siemens, DR; Tannock, IF | 1 |
| Chiu, CC; Hour, TC; Hsu, SH; Hsu, WC; Hu, HT; Huang, AM; Kao, YT; Lin, CS; Lu, CY; Pu, YS | 1 |
| Bachner, M; Cerveny, M; De Santis, M; Dittrich, C; Kametriser, G; Königsberg, R; Schratter-Sehn, A; Sedlmayer, F; Steininger, T | 1 |
| Beardo Villar, P; Gamaza Martínez, R; Gavira Moreno, R | 1 |
| Carbone, A; Di Cristofano, C; Evangelista, S; Palleschi, G; Pastore, AL; Petrozza, V; Porta, N; Rossi, L; Silvestri, L; Tomao, S | 1 |
| Benson, MC; Danzig, MR; Decastro, GJ; Deibert, CM; Ghandour, RA; McKiernan, JM; Stevenson, SM | 1 |
| Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
| Allory, Y; Bouquot, M; Comperat, E; de la Taille, A; Masson-Lecomte, A; Rouprêt, M; Sibony, M; Xylinas, E; Zerbib, M | 1 |
| Groselj, B; Karaszi, K; Kerr, M; Kiltie, AE; Scott, HE; Sharma, NL; Stratford, MR | 1 |
| Aning, J; Barocas, DA; Bivalacqua, TJ; Black, PC; Campain, NJ; Cookson, MS; Dall'Era, MA; Daneshmand, S; Dinney, CP; Ercole, CE; Espiritu, PN; Fairey, AS; Gandhi, NM; Garcia, JA; Griffin, J; Holzbeierlein, JM; Horenblas, S; Jacobsen, NE; Kassouf, W; Krabbe, LM; Lotan, Y; McGrath, JS; Mertens, LS; Mir, MC; Montgomery, JS; Morgan, TM; North, S; Seah, JA; Shah, JB; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Vasdev, N; Wright, JL; Xylinas, E; Youssef, D; Yu, EY; Zargar, H | 1 |
| Kwiatkowski, DJ; Liu, Y | 1 |
| Sun, M; Wu, B; Xie, Q; Zhan, Y; Zhao, W | 1 |
| Agarwal, N; Bellmunt, J; Di Lorenzo, G; Eigl, BJ; Giannatempo, P; Hussain, SA; Locke, J; Necchi, A; Niegisch, G; Pal, SK; Pond, GR; Poole, A; Singh, P; Sonpavde, G; Vaishampayan, UN | 1 |
| Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Sycova-Mila, Z | 1 |
| Agerbaek, M; Albers, P; Charpentier, D; Chester, JD; Collette, L; Daugaard, G; de Santis, M; de Wit, R; Dumez, H; Fossa, SD; Geoffrois, L; Graham, J; Joly, F; Kerst, JM; Leahy, MG; Marreaud, S; Mignot, L; Rolland, F; Sengelov, L; Skoneczna, I; Sternberg, CN; Sundar, S; Sylvester, R; Symonds, P; Thalmann, G; Théodore, C; Verbaeys, A; Witjes, JA; Wood, L | 1 |
| Adshead, J; Boustead, G; Green, JS; Hughes, S; Lamb, BW; Lane, T; Payne, H; Tan, WS; Vasdev, N | 1 |
| Kamat, A | 1 |
| Chau, C; Crabb, SJ; Geldart, T; Wheater, M | 1 |
| Cai, H; Gu, M; Xu, T; Xu, Z; Yu, B; Zhou, J; Zou, Q | 1 |
| Ichimaru, N; Kojima, Y; Nonomura, N; Okumi, M; Takahara, S; Takahi, Y | 1 |
| Culine, S; Gauthier, H; Le Maignan, C; Pouessel, D; Serrate, C; Teixeira, L | 1 |
| Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R | 1 |
| Krabbe, LM; Schmidt, S | 1 |
| Abe, H; Horie, S; Ide, H; Isotani, S; Kamai, T; Kitamura, K; Muto, S; Noguchi, T; Sugiura, S; Yamaguchi, R | 1 |
| Culine, S; Gauthier, H | 1 |
| Papadopoulos, EI; Scorilas, A; Yousef, GM | 1 |
| Chang, C; Guo, H; Huang, X; Li, M; Lu, Q; Xie, B; Yan, J; Yan, X; Yao, X; Ye, C; Zhang, Z; Zhao, W; Zhou, J; Zhuang, J | 1 |
| Agarwal, N; Bellmunt, J; Berthold, D; Chowdhury, S; Crabb, SJ; Galsky, MD; Harshman, LC; Hussain, SA; Ladoire, S; Milowsky, MI; Moshier, EL; Necchi, A; Pal, SK; Powles, T; Recine, F; Rosenberg, JE; Theodore, C; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Antonietti, P; Bartsch, G; Blaheta, R; Cinatl, J; Gessler, F; Haferkamp, A; Kögel, D; Mani, J; Michaelis, M; Rakel, S; Vallo, S | 1 |
| Bracci, L; Brunetti, J; Carini, M; Depau, L; Falciani, C; Lelli, B; Menichetti, S; Minervini, A; Pini, A; Ravenni, N; Siena, G; Tenori, E | 1 |
| Ichioka, D; Inoue, T; Kageyama, S; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Nomoto, T; Shiraishi, Y; Sugimoto, M; Wakeda, H | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Bergman, AM; Bex, A; Horenblas, S; Kerst, JM; Meijer, RP; Mertens, LS; van de Putte, EE; van der Heijden, MS; van der Poel, HG; van Rhijn, BW | 1 |
| Baretton, GB; Froehner, M; Hakenberg, OW; Heberling, U; Hübler, M; Koch, R; Novotny, V; Oehlschlaeger, S; Wirth, MP | 1 |
| Chan, A; De Guzman Langit, MR; Fong, W; Lim, ST; Lim, TA; Song, M; Tang, T; Tay, K | 1 |
| Baras, AS; Berman, D; Bivalacqua, TJ; Faraj, S; Gandhi, N; Hahn, N; Hoque, M; Hoque, MO; Marchionni, L; Munari, E; Netto, G; Schoenberg, M; Shultz, L | 1 |
| Arriaga, Y; Courtney, K; Krabbe, LM; Lotan, Y; Margulis, V; Raj, GV; Sagalowsky, AI; Westerman, ME | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Jinesh, GG; Kamat, AM; Mmeje, CO; Takeuchi, H; Taoka, R | 1 |
| Dumas, G; Goldwasser, F; Rodrigues, MJ; Rousseau, B; Tlemsani, C | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Feng, YH; Huang, KH; Li, CF; Lin, KL; Shen, KH; Tzeng, WS | 1 |
| Chalasani, V; Gunaratne, DA; Krieger, LE; Maclean, F; Vaux, KJ | 1 |
| Dolan, DE; Gupta, S; Jan, AS; Lombardi, K | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Jeong, CW; Kim, HH; Kim, HS; Ku, JH; Kwak, C | 1 |
| Baloğlu, E; Bernkop-Schnürch, A; Çalışkan, Ç; İlem-Özdemir, D; Karavana, SY; Şen, S; Şenyiğit, ZA; Waldner, C | 1 |
| Ishitoya, S; Onishi, H; Takeuchi, E; Terashima, T; Uemura, Y; Ushida, H | 1 |
| Hour, TC; Huang, CN; Huang, HS; Kang, WY; Li, CC; Li, WM; Liu, ZM; Wu, WJ; Yeh, BW | 1 |
| Apolo, AB; Bajorin, DF; Furberg, HF; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Tully, CM; Zabor, EC | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Hagiwara, M; Hanai, K; Ichioka, D; Inoue, T; Kageyama, S; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Sugimoto, M; Wakeda, H; Yamamoto, S; Yuge, K | 1 |
| Bi, D; Ding, K; Ding, S; Li, J; Liu, S; Lu, J; Niu, Z; Sun, L; Wu, F; Zhang, H; Zhao, Z | 1 |
| Jha, V; Ojha, R; Singh, SK | 1 |
| Albiges, L; Bellmunt, J; Culine, S; De Santis, M; Flechon, A; Lin, CC; Loidl, WC; Lucas, C; Mourey, L; Necchi, A; Retz, MM; Senkus-Konefka, E; Su, WC; Vaissière, N; Wiechno, PJ | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Boegemann, M; Krabbe, LM; Schlack, K; Schrader, AJ; Steinestel, J | 1 |
| Gordetsky, JB; Lockhart, ME; Nix, JW; Sonpavde, G | 1 |
| Chain, P; Cimino, G; de Vere White, R; Gleasner, C; Henderson, PT; Hu, B; Lin, TY; Malfatti, M; Mcmurry, K; Pan, AW; Pan, CX; Scharadin, TM; Turteltaub, K; Vinall, R; Vuyisich, M; Wang, S; Zhang, H; Zimmermann, M | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Hattori, Y; Inayama, Y; Ishida, H; Kawahara, T; Kondo, T; Kumano, Y; Maeda, Y; Miyoshi, Y; Mochizuki, T; Ohtaka, M; Teranishi, J; Uemura, H; Yao, M; Yumura, Y | 1 |
| Nepple, KG; O'Donnell, MA; Steinberg, RL; Thomas, LJ; Velaer, KN | 1 |
| Chen, Y; Cheng, K; Li, ZK; Li, ZP; Liu, JY; Yang, Y | 1 |
| Dearnaley, D; Hafeez, S; Hansen, VN; Harris, V; Horwich, A; Huddart, R; Jones, K; Khan, A; Kumar, P; Lalondrelle, S; McDonald, F; McNair, HA; Mohammed, K; Tan, M; Thomas, K; Thompson, A; Warren-Oseni, K | 1 |
| Akise, Y; Hashimoto, S; Kutsuki, S; Miyazawa, M; Nishimoto, K; Uchida, A | 1 |
| Chin, AI; Huang, J; Lee, J; Li, G; Peek, EM; Pellegrini, M; Prado, K; Wang, X; Zhang, H; Zhang, KX | 1 |
| Higa, T; Hyakuna, N; Iraha, S; Kinjyo, T; Kuroda, N; Matsuda, T; Miyazato, Y; Nakama, T; Nakazato, I; Oshiro, K | 1 |
| Albany, C; Bihrle, R; Cary, KC; Cheng, L; Cho, JS; Foster, RS; Gellhaus, PT; Hahn, NM; Kaimakliotis, HZ; Koch, MO; Masterson, TA; Monn, MF; Pedrosa, JA | 1 |
| Amantini, C; Cardinali, C; Gismondi, A; Morelli, MB; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Bi, D; Ding, S; Gao, D; Han, L; Li, C; Li, W; Liu, S; Liu, Z; Lu, J; Niu, Z; Yin, L | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwabuchi, I; Kawaguchi, T; Koie, T; Murasawa, H; Ogasawara, M; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Domingo-Domenech, J; Ferket, BS; Galsky, MD; Sfakianos, JP | 1 |
| Allory, Y; Bastuji-Garin, S; Beuzeboc, P; Chevreau, C; Culine, S; Houédé, N; Le Thuaut, A; Loriot, Y; Pouessel, D; Sevin, E; Taille, A; Vordos, D | 1 |
| Chen, W; Hou, H; Li, X; Pan, J; Wu, W; Xue, M; Zhai, W | 1 |
| Feuz, L; Gee, ME; Krajewski, KC; Kurtzhalts, K | 1 |
| Azria, D; Caffo, O; Choudhury, A; De Santis, M; Fellin, G; Galligioni, E; Hamstra, DA; Kragelj, B; Pappagallo, GL; Thompson, C | 1 |
| Bastuji-Garin, S; Brureau, L; Canoui-Poitrine, F; Carvahlo-Verlinde, M; Culine, S; Demery, ME; Fléchon, A; Laurent, M; Paillaud, E; Thuaut, AL | 1 |
| Cho, MH; Chung, J; Joung, JY; Kim, SH; Lee, KH; Park, WS; Seo, HK | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Funt, SA; Rosenberg, JE | 1 |
| Plimack, ER; Ramamurthy, C; Zibelman, M | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Costello, JC; Kanigel Winner, KR | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Deguchi, T; Fujita, Y; Horie, K; Ito, M; Kameyama, K; Kato, T; Kawakami, K; Kojima, T; Miyazaki, T; Mizutani, K | 1 |
| Agarwal, N; Alva, A; Bamias, A; Bellmunt, J; Casey, MF; Crabb, SJ; De Giorgi, U; Galsky, MD; Harshman, LC; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Powles, T; Ramos, JD; Recine, F; Rosenberg, JE; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Cinatl, J; Hoffmann, MJ; Isono, M; Michaelis, M; Niegisch, G; Pinkerneil, M; Sato, A; Schulz, WA | 1 |
| Hara, I; Iba, A; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nishizawa, S | 1 |
| Booth, CM; Mackillop, WJ; Robinson, AG; Vera-Badillo, FE; Wei, X | 1 |
| Del-Barrio-Díaz-Aldagalan, A; Garrido-Abad, P; López-Elzaurdia, C; Méndez-Rubio, S; Platas-Sancho, A; Rodríguez-Cabello, MA; Saenz-Medina, J; Sanz-Miguelañez, JL | 1 |
| Alsdorf, WH; Avilov, SA; Bokemeyer, C; Dyshlovoy, SA; Hauschild, J; Honecker, F; Kalinin, VI; Madanchi, R; Otte, K; Schumacher, U; Silchenko, AS; Stonik, VA; von Amsberg, G | 1 |
| Alanee, SR; Bajorin, DF; Garcia-Grossman, IR; Littman, J; Offit, K; Ostrovnaya, I; Pendse, DV; Regazzi, AM; Shah, S; Vijai, J; Zabor, EC | 1 |
| Alexandre, J; Blanchet, B; Goldwasser, F; Henon, C; Huillard, O; Preta, LH | 1 |
| Anandadas, C; Choudhury, A; Elliott, T; Joseph, N; Logue, J; Lyons, J; Sanderson, B; Thompson, C; Wylie, J | 1 |
| Desauw, C; Rose, C; Tran, TH | 1 |
| Lebret, T | 1 |
| Nielsen, ME | 1 |
| Bajorin, DF; Bochner, BH; Boyle, MG; Dalbagni, G; Dash, A; Donat, SM; Herr, HW; Milowsky, MI; Pettus, JA; Russo, P | 1 |
| Beekman, K; Dunn, RL; Hussain, M; Lee, CT; Mackler, NJ; Montie, JE; Petrylak, DP; Quinn, DI; Sanda, M; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Lee, CT; Montie, JE; Oh, KS; Sandler, HM; Smith, DC; Soto, DE | 1 |
| Fujisawa, M; Gleave, ME; Hayashi, N; Miyake, H; Muramaki, M; So, A; Sowery, R | 1 |
| Dorff, TB; Miranda, G; Quinn, DI; Skinner, DG; Stein, JP; Tsao-Wei, D | 1 |
| Fujii, Y; Kawakami, S; Kihara, K; Kobayashi, T; Koga, F; Masuda, H; Nakayama, T; Saito, K; Yoshida, S | 1 |
| Lebret, T; Méjean, A | 1 |
| Kanai, K; Kikuchi, E; Miyajima, A; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Campbell, SC; Dreicer, R; Fergany, AF; Garcia, JA; Gong, MC; Hansel, DE; Jones, JS; Klein, EA; Stephenson, AJ; Weight, CJ | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Fiorito, C; Gontero, P; Lucca, I; Tizzani, A; Valentino, F | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wu, PH; Xiong, YH; Yu, SL; Zhou, FJ | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Bartel, P; Ecke, TH; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Bätge, R; Egberts, EH; Holstein, A | 1 |
| Böhle, A; Büttner, H; Frei, C; Helsberg, K; Knispel, HH; Kühn, M; Leyh, H; Lübben, B; Pottek, T; Soldatenkova, V; Stoffregen, C; Tschada, R; von Pokrzywnitzki, W; Wagner, W; Zorlu, F | 1 |
| Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
| Cass, CE; Damaraju, S; Damaraju, VL; Mowles, D; Sawyer, MB | 1 |
| Aggarwal, BB; Inamoto, T; Kamat, AM; Sung, B; Tharakan, ST | 1 |
| Campodonico, F; Maffezzini, M; Martelli, A; Mattioli, F; Puntoni, M | 1 |
| Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Abbruzzese, A; Addeo, R; Bellini, S; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Lanna, M; Miragliuolo, A; Montella, L; Vincenzi, B | 1 |
| Autorino, R; Bruni, G; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Federico, P; Gallo, L; Masala, D; Perdonà, S; Pizzuti, M; Quattrone, C | 1 |
| Berglund, RK | 1 |
| Twombly, R | 1 |
| Hudson, E; Lester, JF | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Ascierto, P; Autorino, R; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Faiella, A; Perdonà, S; Pignata, S; Simeone, E | 1 |
| Bini, V; Costantini, E; Del Zingaro, M; Giannantoni, A; Lazzeri, M; Mearini, L; Porena, M | 1 |
| Rouprêt, M; Yates, DR | 1 |
| Conrad, S; Heer-Sonderhoff, A; Schmorl, P; Vosshenrich, R | 1 |
| Cho, JS; Cho, KS; Chung, BH; Doo, SH; Hong, SJ; Kim, CI; Kim, SJ; Song, KH; Song, YS; Yang, WJ | 1 |
| Fujiwara, H; Hagiuda, J; Hoshino, H; Kikuchi, E; Maeda, T; Matsumoto, K; Miyajima, A; Nakagawa, K; Oya, M; Yazawa, S | 1 |
| Siefker-Radtke, A | 2 |
| Bonfill Abella, T; Dalmau Pórtulas, E; Gallardo-Díaz, E; Moya-Horno, I; Pericay Pijaume, C; Querol Niñerola, R; Saigí Grau, E | 1 |
| da Silva Passos Júnior, GA; da Silva, GN; de Camargo, EA; de Castro Marcondes, JP; Sakamoto-Hojo, ET; Salvadori, DM | 1 |
| Johnson, CS; Ma, Y; Trump, DL; Yu, WD | 1 |
| Berta, G; Carbone, F; Cattel, L; Fiorito, C; Gontero, P; Medana, C; Milla, P; Paone, TC; Tizzani, A | 1 |
| Anai, S; Fujimoto, K; Hirao, Y; Ikeda, T; Inoue, T; Matsumura, Y; Miyake, M; Nakai, Y; Ohnishi, S; Okajima, E; Tanaka, N; Tomioka, A | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Pipiriene-Zelviene, T | 1 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Katsuoka, Y; Kiyama, S; Komura, K; Kotake, Y; Narumi, Y; Nomi, H; Takahara, K; Ubai, T; Uehara, H; Yamamoto, K | 2 |
| Burkhard, FC; Gautschi, O; Ghadjar, P; Studer, UE; Thalmann, GN | 1 |
| Galettis, P; Manners, S; Souza, Pd | 1 |
| Abolhassani, M; Baronzio, G; Behzadi, M; Campion, F; Fiorentini, G; Guais, A; Mainini, C; Montagnani, F; Sanders, E; Schwartz, L | 1 |
| Aoki, K; Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Nishida, T; Sasaki, T; Shimamoto, K; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Graffer, U; Mussari, S; Tomio, L | 1 |
| de Vere White, R; Henderson, P; Lara, PN; Malfatti, M; Pan, CX; Turteltaub, K; Wang, S; Zhang, H | 1 |
| Chang, JS; Hsieh, YH; Huang, CT; Huang, YB; Tsai, YH; Wu, PC | 1 |
| Asakura, H; Deguchi, N; Fukuyama, R; Horinaga, M; Iida, M; Nakahira, Y; Nonaka, S; Yanaihara, H | 1 |
| Cheng, L; Evans, C; Pan, CX; Wang, S; Zhang, H | 1 |
| Ayuso, D; Becht, C; Culine, S; Huguet, H; Iborra, F; Pouessel, D; Rebillard, X | 1 |
| Hara, I; Inagaki, T; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nanpo, Y; Ohashi, Y; Yasuoka, H | 1 |
| Balandra, A; Bergey, MR; Canter, DJ; Guzzo, TJ; Magerfleisch, L; Malkowicz, SB; Resnick, MJ; Tomaszewski, JE; Vaughn, DJ | 1 |
| Bottomley, I; Choudhury, A; Clarke, NW; Cowan, RA; Elliott, PA; Kiltie, AE; Livsey, JE; Logue, JP; Lyons, J; McCaul, D; Ramani, V; Sangar, V; Swindell, R; Symonds, P; Wise, M; Wylie, JP | 1 |
| Chen, YG; Lin, GM; Lin, JC; Lin, TY | 1 |
| Rexer, H | 3 |
| Arranz, EM; Arranz, MD; Bellido, EC; Cabral, JM; García, AB; Juberías, LA; Kreilinger, JJ; Parga, JM; Prianes, LA; Robledo, JP; Sanz, RR; Sanz-Agero, PG; Serrano, EM | 1 |
| Norby, SM; Sethi, S; Thomas, JG | 1 |
| Ashikari, A; Ashimine, S; Haranaga, S; Machida, N; Matsumura, E; Oshiro, Y; Saito, S; Tasaki, S; Toyosato, T | 1 |
| Hahn, NM; Johnson, CS; Nattam, S; Perkins, SM; Picus, J; Stadler, WM; Sweeney, CJ; Waddell, MJ; Waterhouse, D; Zon, RT | 1 |
| Chao, SY; Chou, CH; Hour, TC; Hu, HT; Huang, AM; Kao, YT; Lin, PY; Liou, JY; Lu, CY; Pu, YS; Toh, S | 1 |
| Bertz, S; Birkenkamp-Demtroder, K; Bødker, JS; Dyrskjøt, L; Hartmann, A; Lehmann, J; Nordentoft, I; Orntoft, TF; Wild, PJ | 1 |
| Cleves, A; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E | 1 |
| Mak, AL; Moibi, JA; Moore, RB; Sun, B | 1 |
| Brausi, M; Fiorito, C; Gontero, P; Oderda, M; Pappagallo, G | 1 |
| Hara, I; Matsumura, N | 1 |
| Colaço, A; Lopes, C; Oliveira, PA; Palomino, LF; Santos, L; Vala, H; Vasconcelos-Nóbrega, C | 1 |
| Kaneko, G; Kikuchi, E; Matsumoto, K; Miyajima, A; Nakamura, S; Obata, J; Oya, M | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Cleves, A; Mason, MD; Shelley, MD; Wilt, TJ | 1 |
| Fisher, SG; Golijanin, D; Messing, EM; Peterson, DR; Sahasrabudhe, D; Scosyrev, E; van Wijngaarden, E | 1 |
| Shariat, SF; Sonpavde, G | 1 |
| Kanetake, H; Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H | 1 |
| Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N | 1 |
| Jensen, JB; Jensen, KM; Ulhøi, BP | 1 |
| Boccardo, F; Cognetti, F; Felici, A; Gallucci, M; Giannarelli, D; Massidda, B; Muto, G; Pollera, CF; Rubagotti, A; Ruggeri, EM | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Borut, K; Lijana, ZK | 1 |
| Baba, S; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K | 1 |
| Culine, S; Fléchon, A; Gourgou, S; Guillot, A; Houédé, N; Joly, F; Le Moulec, S; Mignot, L; Oudard, S; Pouessel, D; Ravaud, A; Rolland, F | 1 |
| Byun, SS; Hong, SK; Jeon, HG; Jeong, SJ; Lee, JE; Lee, SE; Park, MJ; Yoon, CY; Yu, JH | 1 |
| Ito, H; Kawahara, T; Kubota, Y; Makiyama, K; Oshiro, H; Sekiguchi, Z; Uemura, H | 1 |
| Ohlmann, CH; Stöckle, M | 1 |
| Abbruzzese, A; Altieri, V; Buonerba, C; Caraglia, M; Di Lorenzo, G; Facchini, G; Ferro, M; Giuberti, G; Perdonà, S; Porto, S; Sperlongano, P; Zappavigna, S | 1 |
| Montie, JE | 2 |
| Altieri, V; Bono, AV; Brausi, MA; Colombo, R; Conti, I; Gontero, P | 1 |
| Pai, KS; Park, SJ; Shin, JI | 1 |
| Costantini, C; Millard, F | 1 |
| Fukuta, F; Kunishima, Y; Kyoda, Y | 1 |
| Badalato, GM; Benson, MC; Hruby, G; McKiernan, JM; Petrylak, DP; RoyChoudhury, A; Wosnitzer, MS; Yeshchina, O | 1 |
| Hashimoto, Y; Hatakeyama, S; Imanishi, K; Kamimura, N; Koie, T; Ohyama, C; Okamoto, A; Okamoto, T; Tokui, N; Yoneyama, T | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, MD; Shelley, MD; Wilt, TJ | 1 |
| Dakeshita, H; Kinoshita, M; Morita, A; Nomata, K; Ogawa, M; Ozeki, A; Tsuruta, T; Yoshioka, H | 1 |
| Albiges, L; Blesius, A; Culine, S; Edeline, J; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Hashmi, A; Masood, R; Qayyum, A; Rafi, M; Tunio, MA | 1 |
| Au-Yeung, G; Davis, ID; Liew, MS | 1 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| Arbea, L; Aristu, J; Gil-Bazo, I; Moreno-Jimenez, M; Perez-Gracia, JL; Rodríguez-Ruiz, ME; San Miguel, I | 1 |
| Fukui, I; Kitsukawa, S; Komai, Y; Kubo, Y; Okubo, Y; Saito, K; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J | 1 |
| Bellmunt, J; Carles, J; Gallén, M; Guix, M; Morales-Barrera, R; Serrano, C; Suárez, C; Valverde, C | 1 |
| Arantes-Rodrigues, R; Cardoso, ML; Colaço, A; Gaivão, I; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Arslan, M; Ceylan, Y; Degirmenci, T; Gunlusoy, B; Kara, C; Kozacıoğlu, Z; Vardar, E | 1 |
| Hwang, EC; Hwang, IS; Hwang, JE; Jung, SI; Kang, TW; Kim, SO; Kwon, DD; Park, K; Ryu, SB; Yu, HS | 1 |
| Abotouk, N; Halim, A | 1 |
| Dinney, CP; Grossman, HB; Kamat, AM; Millikan, RE; Shen, Y; Siefker-Radtke, AO; Williams, DL | 1 |
| Pal, SK; Ruel, NH; Wilson, TG; Yuh, BE | 1 |
| Hashimoto, Y; Hatakeyama, S; Kamimura, N; Koie, T; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Ashimine, S; Kimura, R; Machida, N; Matsumura, E; Miyagi, R; Miyazato, M; Oshiro, Y; Saito, S | 1 |
| da Silva, GN; de Camargo, EA; Salvadori, DM | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Mussari, S; Russo, L; Veccia, A | 1 |
| Pal, SK; Ruel, N; Vogelzang, N; Wilson, TG; Yuh, BE | 1 |
| Itoh, K; Matsubara, N; Mukai, H; Naito, Y; Nezu, M | 1 |
| Aravantinos, G; Bamias, A; Chrisophos, M; Constantinidis, C; Dafni, U; Deliveliotis, C; Dimopoulos, MA; Eleftheraki, A; Fountzilas, G; Hatzimouratidis, C; Karadimou, A; Koutoulidis, V; Pectasides, D; Psyrri, A; Samantas, E; Stravodimos, K; Timotheadou, E; Tsiatas, M; Visvikis, A; Xanthakis, I | 1 |
| Cai, J; Daneshmand, S; Dorff, T; Dorin, R; Fairey, AS; Lieskovsky, G; Miranda, G; Quinn, D; Schuckman, A; Skinner, EC | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Fujioka, T; Iwasaki, K; Kato, Y; Obara, W; Takata, R; Tanji, S | 1 |
| Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tani, S; Tani, T | 1 |
| Açikalin, M; Başeskioglu, B; Can, C; Duman, BB; Kara, IO; Yildirim, M | 1 |
| Vogelzang, NJ | 2 |
| Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK | 1 |
| Cheon, J; Choi, IK; Kang, SG; Kang, SH; Kim, HS; Kim, JS; Kim, ST; Kim, YH; Ko, YH; Lee, SW; Oh, SC; Park, JH; Park, KH; Park, YJ; Seo, JH; Sung, DJ | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Asse, E; Kallwellis, G; Klebingat, KJ; Protzel, C; Zimmermann, U | 1 |
| Crawford, ED | 1 |
| Bajorin, D; Dalbagni, G; dePalma, D; Donat, MS; Herr, HW; Mazumdar, M; Rabbani, F; Russo, P; Sheinfeld, J; Sogani, P; Tong, W | 1 |
| Hanel, EG; Karmali, S; Kilani, RT; Mackey, J; Moore, RB; Tamimi, Y; Wong, KK | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Antonuzzo, A; Chioni, A; Conte, P; Francesca, F; Galli, L; Iannopollo, M; Orlandini, C; Ricci, S; Selli, C; Vocaturo, V | 1 |
| Culine, S | 2 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Albers, P; Lehmann, J; Lippert, C; Retz, M; Stöckle, M | 1 |
| Egorin, MJ; Eisenberger, MA; Haisfield-Wolf, ME; Laufer, M; Nativ, O; Ramalingam, S; Schoenberg, MP; Trueheart, IN; Zuhowski, EG | 1 |
| Akman, Y; Alper, M; Cam, K; Kavak, A | 1 |
| Albers, P; Blatter, J; Fechner, G; Haase, L; Ludwig, E; Mller, SC; Perabo, FG; Schmidt, DH; Schueller, H | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Bellmunt, J; de Wit, R | 1 |
| Alonso Rodrigo, A; Barros Rodríguez, JM; Benavente Delgado, J; Domínguez Freire, F; González Piñeiro, A; López Bellido, D; Núñez López, A; Ojea Calvo, A; Otero García, M; Rodríguez Iglesias, B | 1 |
| Aksoy, Y; Kadioğlu, YY; Yilmaz, B | 1 |
| Carini, M; Corvino, C; Lapini, A; Meliani, E; Serni, S | 1 |
| Hussain, SA; James, ND | 1 |
| Bodrogi, I | 1 |
| Dundr, P; Dvorácek, J; Pesl, M; Povýsil, C; Vítková, I | 1 |
| Peters, GJ; Schalken, JA; van der Heijden, AG; Vriesema, JL; Witjes, JA | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Genet, D; Labourey, JL; Ly, K; Martin, J; Szelag, JC; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Ariad, S; Cohen, AD; Grunwald, M; Lazarev, I; Mermershtain, W | 1 |
| Gschwend, JE; Hautmann, RE; Simon, J; Volkmer, B | 1 |
| Bolner, A; Caffo, O; Fellin, G; Galligioni, E; Graffer, U; Luciani, L; Tomio, L; Valduga, F | 1 |
| Baltaci, S; Bedük, Y; Göğüş, C; Göğüş, O; Türkölmez, K | 1 |
| Kurokawa, S; Matsuzaki, A; Morita, T; Tokue, A | 1 |
| Chiba, H; Hirayama, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Laan, A; Peters, GJ; Schalken, JA; van der Heijden, AG; Vriesema, JL; Witjes, JA | 1 |
| Clarke, NW; Cowan, R; Hendry, JH; Margison, GP; Sangar, VK | 1 |
| Ali, SA; Fareed, A; Mallick, JA; Siddiqui, N | 1 |
| Akar, S; Akkoc, N; Birlik, M; Kirkali, Z; Manisali, M; Onen, F; Ozer, E; Tuzel, E | 1 |
| Amadori, D; Fabbri, F; Frassineti, GL; Gasperi Campani, A; Gunelli, R; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Amsellem-Ouazana, D; Beuzeboc, P; Debre, B; Peyromaure, M; Viellefond, A; Zerbib, M | 1 |
| Antonini, G; Codacci-Pisanelli, G; De Berardinis, E; Di Silverio, F; Loves, WJ; Peters, GJ; Van der Born, K | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Eto, H; Gleave, ME; Hara, I; Li, D; Miyake, H; So, A | 1 |
| Chester, JD; Forster, M; Hall, GD; Protheroe, AS | 1 |
| Chung, YL; Griffiths, JR; Harris, AL; Judson, IR; Leach, MO; Leek, R; Stubbs, M; Troy, H | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Esper, P; Fardig, J; Herman, J; Kent, E; Lee, C; Montie, J; Sandler, H; Smith, DC | 1 |
| Esper, P; Griffith, KA; Hayman, JA; Herman, JM; Kent, E; Montie, J; Sandler, HM; Smith, DC; Sullivan, MA | 1 |
| Carcas, A; Duque, B; Garcia-Ribas, I; Palou, J; Salvador, J; Segarra, J; Villavicencio, H | 1 |
| Geh, JI; Hussain, SA; James, ND; Palmer, DH; Peake, DR; Riley, P; Spooner, D; Stocken, DD | 1 |
| Casetta, G; Frea, B; Gontero, P; Maso, G; Pretti, G; Sogni, F; Tizzani, A; Zitella, A | 1 |
| Codacci-Pisanelli, G; Kroep, JR; Loves, W; Peters, GJ; Sigmond, J | 1 |
| Anagnostopoulos, A; Aravantinos, G; Athanasios Dimopoulos, M; Bafaloukos, D; Bamias, A; Deliveliotis, C; Efstathiou, E; Kalofonos, C; Linardou, H | 1 |
| deVere White, RW; Ellison, LM; Gandour-Edwards, R; Goldberg, Z; Karpman, E; Saffarian, A | 1 |
| Hansen, SW; Larsen, FO | 1 |
| Hara, I; Kamidono, S; Kawabata, G; Miyake, H; Muramaki, M | 1 |
| Bertetto, O; Botta, M; Castagneto, B; Ferraris, V; Marenco, D; Mencoboni, M; Repetto, L; Scaltriti, L; Zai, S | 1 |
| Freiha, F; Morgan, K; Srinivas, S | 1 |
| Aronson, M; Dalal, E; Laufer, M; Nativ, O; Sabo, E | 1 |
| Boutry, N; Brénuchon, C; Devulder, B; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Maurage, CA; N'Guyen, HD; Queyrel, V | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wang, B; Wang, H; Yu, SL; Zhou, FJ | 1 |
| Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M | 1 |
| Comella, P; Crucitta, E; De Lena, M; Gebbia, V; Lorusso, V; Mancarella, S; Mangiameli, A; Manzione, L; Muci, D; Palmeri, S; Pezzella, G; Rosati, G; Silvestris, N; Sobrero, A | 1 |
| Allegro, R; Galuffo, A; Pavone, C; Pavone-MacAluso, M; Serretta, V | 1 |
| Clarke, NW; Cowan, RA; Logue, JP; Lyons, J; McBain, CA; Ramani, VA; Sangar, VK; Wylie, JP | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Jansen, CF; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA | 1 |
| Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T | 1 |
| Guardino, AE; Srinivas, S | 1 |
| Aristides, M; Bhalla, S; Brown, A; Kielhorn, A; Roberts, T; Von Der Maase, H | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Litchy, S; Meluch, AA; Schnell, FM; Yost, K | 1 |
| Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP | 1 |
| Fontana, J; Forman, J; Frazier, A; Patel, B; Pontes, E; Vaishampayan, U | 1 |
| Arning, M; Dogliotti, L; Moore, MJ; Oliver, T; Ricci, S; Roberts, JT; Sengelov, L; von der Maase, H; Zimmermann, A | 1 |
| Böhle, A; Brocks, CP; Büttner, H | 1 |
| Beckman, E; Carringer, M; Gårdmark, T; Malmström, PU | 1 |
| Iba, A; Kohjimoto, Y; Shinka, T; Shintani, Y; Uekado, Y | 1 |
| Badger, J; Kang, S; Srinivas, S; Uzieblo, A | 1 |
| Frea, B; Gontero, P; Marini, L | 1 |
| Bartoletti, R; Cai, T; Gacci, M; Ghezzi, P; Giubilei, G; Nerozzi, S; Repetti, F; Santelli, G; Sisani, M; Viggiani, F | 1 |
| Campodonico, F; Maffezzini, M | 1 |
| Simpson, A | 1 |
| Crausaz, S; Metcalfe, S | 1 |
| Adamo, B; Adamo, V; Alafaci, E; Garipoli, C; Magno, C; Maisano, C; Rossello, R; Scandurra, G; Scimone, A; Spitaleri, G | 1 |
| Bassi, P; Crucitta, E; Dal Moro, F; De Marco, V; Longo, F; Marini, L; Pinto, F; Tavolini, IM; Zucchetti, M | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, HP; Kastritis, E; Koutras, A; Linardou, H; Moulopoulos, LA; Pectasides, D; Skarlos, D | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Friedrich, C; Krege, S; Pientka, L; Rübben, H | 1 |
| Canil, C; Chi, KN; Moore, M; Murray, RN; Tinker, A; Winquist, E | 1 |
| Koga, H; Naito, S | 1 |
| Bartoletti, R; Cai, T; Carini, M; Gacci, M; Ghezzi, P; Nerozzi, S; Nesi, G; Pinzi, N; Repetti, F; Viggiani, F | 1 |
| Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
| Ash, R; Passaperuma, K; Rodrigues, G; Venkatesan, V; Winquist, E | 1 |
| Castelli, E; Casu, M; Conti, G; Cretarola, E; D'Urso, L; Ferrando, U; Francesca, F; Graziano, ME; Hurle, R; Lancini, V; Lissoni, G; Luporini, AC; Morabito, F; Muto, G; Razionale, P; Rossi, R; Simone, M; Sommariva, M | 1 |
| Bajorin, D; Ben-Porat, L; Bochner, B; Dalbagni, G; Donat, MS; Herr, HW; Russo, P; Sheinfeld, J; Sogani, P | 1 |
| Albiol, S; Bellmunt, J; de Olano, AR; Maroto, P; Pujadas, J | 1 |
| Arning, M; Conte, PF; Dogliotti, L; Moore, MJ; Oliver, T; Roberts, JT; Sengeløv, L; von der Maase, H; Zimmermann, A | 1 |
| Frea, B; Gontero, P | 1 |
| Adorini, L; Daniel, KC; Penna, G | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F | 1 |
| Chen, G; Geertsen, PF; Gough, J; Gravis, G; Joensuu, H; Kania, M; Lehmann, J; von der Maase, H | 1 |
| Lehmann, J; Retz, M; Schreier, U; Siemer, S; Stöckle, M; Zwergel, U | 1 |
| Hendricksen, K; Witjes, JA | 1 |
| Beuzeboc, P; Chevreau, C; Culine, S; Fizazi, K; Fléchon, A; Geoffrois, L; Gourgou-Bourgade, S; Mottet, N; Théodore, C | 1 |
| Dinney, CP; Highshaw, R; Kamat, AM; Kassouf, W; Nelkin, GM | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Huo, D; Jin, JO; Lehmann, J; Stadler, WM; Steinberg, G; Stöckle, M; Taxy, J; Vogelzang, NJ | 1 |
| Campodonico, F; Canepa, G; Capponi, G; Fontana, V; Maffezzini, M | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Clenton, SJ; Ferguson, CJ; Kirkbride, P | 1 |
| Albanell, J; Carles, J; Doménech, M; Fabregat, X; Font, A; Gallén, M; Mesía, C; Nogué, M; Suárez, C; Suárez, M; Tusquets, I | 1 |
| Bartel, P; Ecke, TH; Koch, S; Ruttloff, J; Theissig, F | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Zelviene, TP | 1 |
| Aglianò, AM; Frati, L; Gandini, O; Gazzaniga, P; Gianni, W; Gradilone, A; Morrone, S; Scarpa, S; Silvestri, I | 1 |
| Aerts, R; De Boeck, G; De Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Martens, M; Selleslach, J; van Oosterom, AT | 1 |
| Alés, I; Baena, V; Benavides, M; Bretón, JJ; Carabante, F; Cobo, M; Contreras, J; Del Rosal, JM; Delgado, R; Fuentes, C; García, E; Gil, S; Herruzo, I; Moreno, P; Ruiz, JL; Villar, E | 1 |
| Ozawa, A; Shimamoto, K; Shirato, A; Tanji, N; Yokoyama, M | 1 |
| Hoshi, S; Kobayashi, T; Muto, A; Ono, K; Sasaki, M; Saso, S; Sugano, O; Suzuki, K; Tukigi, M | 1 |
| Bajorin, DF; Boyle, MG; Galsky, MD; Iasonos, A; Mironov, S; Scattergood, J | 1 |
| Amadori, D; Bertetto, O; Bono, A; Cartenì, G; Dogliotti, L; Marini, L; Martoni, A; Onat, H; Siena, S | 1 |
| Albiol, S; Baselga, J; Bellmunt, J; Carles, J; Cecere, FL; Cuello, M; de la Cruz, JJ; Gallardo, E; Guillem, V; Mendez, P; Paz-Ares, L; Rosell, R; Taron, M | 1 |
| Cho, H; Conaway, M; Hampton, G; Havaleshko, DM; Lee, JK; Owens, CR; Theodorescu, D | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Cheng, AL; Hsu, CH; Huang, CY; Huang, KH; Keng, HY; Lin, CC; Pu, YS; Tsai, YC | 1 |
| González, C; Morís, G; Ribacoba, R | 1 |
| Aggarwal, BB; Kamat, AM; Sethi, G | 1 |
| Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Als, AB; Sengelov, L; von der Maase, H | 2 |
| Gschwend, JE | 1 |
| Bartoletti, R; Cai, T; Farina, U; Mazzoli, S; Melone, F; Mondaini, N | 1 |
| Conti, G | 1 |
| Gontero, P | 1 |
| Vaughn, DJ | 1 |
| Chatta, GS; Chen, H; Dunn, RL; Glode, LM; Hussain, MH; Lara, PN; MacVicar, GR; Nanus, DM; Petrylak, DP; Smith, DC; Trump, DL; Vaishampayan, U | 1 |
| Fang, WJ; Qian, J; Xiong, JP; Xu, N; Yu, LF; Zhang, L; Zhang, XC | 1 |
| Hariharan, S; Welsh, CH | 1 |
| Brausi, MA | 1 |
| Géczi, L | 1 |
| Albanell, J; Bellmunt, J; Berrocal, A; Carles, J; Climent, M; Esteban, E; Fabregat, X; Font, A; Garcia-Ribas, I; Gonzalez-Larriba, JL; Marfa, X | 1 |
| Hartley, A; Ho, K; Muscroft, T; Sanghera, P | 1 |
| Burks, T; Chaudhary, UB; Curry, N; Sawhney, R | 1 |
| Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T | 1 |
| Ballardini, M; Bercovich, E; Fiori, M; Frassineti, GL; Giovannini, N; Gunelli, R; Nanni, O; Pappagallo, GL; Pasquini, E; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| El Karak, F; Flechon, A | 1 |
| Aglianò, AM; Gazzaniga, P; Gradilone, A; Silvestri, I | 1 |
| Bakirtas, H; Eroglu, M; Guvence, N; Ozok, HU; Ure, M | 1 |
| Aletti, M; Bauduceau, O; Bonnichon, A; Borne, M; Ceccaldi, B; Fayolle, M; Le Moulec, S; Margery, J; Vedrine, L | 1 |
| Rödel, C; Sauer, R; Weiss, C | 2 |
| Hagisawa, S; Hatakeyama, S; Imai, A; Ishimura, D; Iwabuchi, I; Koie, T; Mori, K; Ohyama, C; Okamoto, A; Yamato, T; Yoneyama, T | 1 |
| Atienza, D; Awasthi, S; Berry, W; Delaune, R; Deutsch, M; Dien, PY; Gregory, TF; Hood, K; Hutson, TE; Ilegbodu, D; Kolodziej, MJ; Mull, S; Muscato, JJ; Nicol, S; Raju, RN; Ruxer, RL; Vukelja, S | 1 |
| Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T | 1 |
| Bastos Oreiro, M; López Rodríguez, M; Monedero Martín, MC; Plasencia Rodríguez, C | 1 |
| Cooney, MM; Dreicer, R; Li, H; Roth, BJ; Wilding, G | 1 |
| Roth, BJ | 1 |
| Bajorin, DF; Roth, BJ | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Pollera, CF | 1 |
| Abi-Aad, AS | 1 |
| Dorr, FA; Kuzel, TM; Levine, E; Raghavan, D; Roth, B; Stadler, WM; Vogelzang, NJ | 1 |
| Dorr, FA; Kuzel, T; Raghavan, D; Roth, B; Stadler, WM | 1 |
| Ernst, DS; Huan, S; Moore, MJ; Murray, N; Tannock, IF | 1 |
| Fagbemi, SO; Stadler, WM | 1 |
| Antoine, EC; Khayat, D | 1 |
| Stadler, WM; Vogelzang, NJ | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Bennett, K; Huan, S; Moore, MJ; Murray, N; Seymour, L; Tannock, IF; Walsh, W; Winquist, EW | 1 |
| Sternberg, CN | 2 |
| Akaza, H; Hattori, K | 1 |
| von der Maase, H | 5 |
| Carles, J; Domènech, M; Guasch, I; Ibeas, R; Nogué, M; Pérez, C; Saigí, E; Villadiego, K | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Cortés-Funes, H; González-Larriba, JL; Guillem, V; Paz-Ares, L; Tabernero, JM | 1 |
| Gaafar, R; Hamza, MR; Khaled, HM; Mansour, O; Zaghloul, MS | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Albers, P; Bodrogi, I; Cleall, SP; Conte, PF; Dogliotti, L; Hansen, SW; Kerbrat, P; Knuth, A; Lippert, CM; Moore, MJ; Oliver, T; Roberts, JT; Roychowdhury, DF; Sanchez Rovira, P; Tomlin, I; Visseren-Grul, CM; von der Maase, H; Wersall, P | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Edelman, MJ | 1 |
| Cohen, MH; Rothmann, M | 1 |
| Ryan, CW; Vogelzang, NJ | 1 |
| Malkowicz, SB; Vaughn, DJ | 2 |
| Du, W; Hussain, M; Redman, B; Smith, DC; Vaishampayan, U | 1 |
| Cohen, EE; Stadler, WM | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Johnson, V; Meluch, AA; Morrissey, LH; O'Rourke, T; Ortega, G; Steis, RG | 1 |
| Logothetis, CJ; Millikan, RE; Plunkett, WK; Smith, TL; Williams, DL | 1 |
| Soloway, MS | 1 |
| Kielb, SJ; Rubin, MA; Sanda, MG; Shah, NL | 1 |
| Albiol, S; Bellmunt, J | 1 |
| Carles, J; Nogué, M | 1 |
| Sun, W; Vaughn, DJ | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; de Wit, R | 1 |
| Froehner, M; Gaertner, HJ; Manseck, A; Wirth, MP | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| de Wit, R | 1 |
| Bagrova, SG | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| Albers, P; Blatter, J; Fallahi, M; Haeutle, D; Härtlein, M; Müller, SC; Perabo, FG; Siener, R; Steiner, G | 1 |
| Stadler, WM | 1 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Misset, JL | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Fujikawa, K; Fukuzawa, S; Iwamura, H; Matsui, Y; Oka, H; Takeuchi, H | 1 |
101 review(s) available for deoxycytidine and Bladder Cancer
| Article | Year |
|---|---|
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Comparative Effectiveness Research; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Outcome Assessment, Health Care; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
Topics: Administration, Intravesical; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Mitomycin; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms | 2023 |
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
Topics: Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Network Meta-Analysis; Urinary Bladder Neoplasms | 2023 |
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Combination Intravesical Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Deoxycytidine; Epirubicin; Ethanol; Forecasting; Gemcitabine; Humans; Indolequinones; Injections, Intralesional; Interferon-alpha; Interleukin-2; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2020 |
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Mitomycin; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2020 |
The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Urinary Bladder Neoplasms | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Bias; Cause of Death; Confidence Intervals; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Saline Solution; Urinary Bladder Neoplasms | 2021 |
[Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; BCG Vaccine; Conservative Treatment; Deoxycytidine; Drug Resistance, Viral; Gemcitabine; Humans; Immunotherapy; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2017 |
[Metastases of Urothelial Carcinoma with Trophoblastic Differentiation that Responded to Combination Chemotherapy with Gemcitabine and Oxaliplatin : A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oxaliplatin; Urinary Bladder Neoplasms | 2018 |
[New endovesical chemotherapy drugs and application vehicles.]
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2018 |
Immune checkpoint inhibitors for urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Nivolumab; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2018 |
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Methotrexate; Nivolumab; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2019 |
[Medical treatment of bladder carcinoma].
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Cisplatin; Cystoscopy; Deoxycytidine; Doxorubicin; Fluorescence; Gemcitabine; Humans; Methotrexate; Mitomycin; Photosensitizing Agents; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Lentinan; Urinary Bladder Neoplasms; Urothelium | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Ultrasonography; Urinary Bladder Neoplasms | 2016 |
Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder Neoplasms | 2016 |
Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Cystectomy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2016 |
Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Lymphatic Metastasis; Male; Pelvis; Radiotherapy; Retroperitoneal Space; Urinary Bladder Neoplasms | 2016 |
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chondrosarcoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; DNA Repair; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy; Lymphatic Metastasis; Muscle Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Organ Sparing Treatments; Preoperative Care; Randomized Controlled Trials as Topic; Time Factors; Urinary Bladder Neoplasms | 2017 |
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; CTLA-4 Antigen; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasm Proteins; Nivolumab; Oncolytic Virotherapy; Programmed Cell Death 1 Receptor; Therapies, Investigational; Urinary Bladder Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Urinary Bladder Neoplasms | 2017 |
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Cystoscopy; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2008 |
Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2010 |
Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasiveness; Risk Factors; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
[Signet ring cell carcinoma of the ampulla of Vater].
Topics: Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Jaundice, Obstructive; Jejunum; Liver; Lymphoma, Follicular; Male; Neoplasm Invasiveness; Neoplasms, Second Primary; Pancreatectomy; Pancreaticoduodenectomy; Splenectomy; Urinary Bladder Neoplasms | 2011 |
[A case of interstitial pneumonia during gemcitabine and cisplatin chemotherapy for locally advanced bladder cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Urinary Bladder Neoplasms | 2011 |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
[When should systemic chemotherapy be used for urinary bladder carcinoma?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Guideline Adherence; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Update on chemotherapy in the treatment of urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms | 2011 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2012 |
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Urinary Bladder Neoplasms | 2012 |
Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Carboplatin; Carcinoma, Transitional Cell; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fractures, Spontaneous; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Pemetrexed; Radiosurgery; Radiotherapy, Conformal; Rib Fractures; Ribs; Spinal Fractures; Thoracic Vertebrae; Urinary Bladder Neoplasms | 2012 |
Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Urinary Bladder Neoplasms | 2002 |
[Gemcitabine and urogenital tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Germinoma; Hematologic Diseases; Humans; Kidney Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Patient Selection; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms; Vinblastine | 2002 |
[Gemcitabine in advanced bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Neoplasm Staging; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2003 |
Overview of gemcitabine triplets in metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2003 |
[Mucinous adenocarcinoma of the urachus].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; Male; Middle Aged; Neoplasm Proteins; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2003 |
The systemic treatment of advanced and metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2003 |
[Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Genes, p53; Genetic Therapy; Humans; Immunologic Factors; Neoadjuvant Therapy; Phenotype; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Analysis of treatment for small cell cancer of the bladder and report of three cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Biomarkers, Tumor; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease Progression; Etoposide; Gemcitabine; Humans; Life Tables; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Prostatectomy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Patient Selection; Urinary Bladder Neoplasms | 2005 |
[Geriatric urology -- tumour diseases].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Male; Middle Aged; Patient Care Team; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2006 |
[Recent progress in the treatment for urothelial cancer].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Doxorubicin; Endoscopy, Gastrointestinal; Evidence-Based Medicine; Gemcitabine; Humans; Laparoscopy; Laser Therapy; Methotrexate; Neoadjuvant Therapy; Taxoids; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2006 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Comorbidity; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Pharmacogenetics; Prognosis; Renal Insufficiency; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2006 |
Actual experience and future development of gemcitabine in superficial bladder cancer.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2006 |
Intravesical gemcitabine: an update of clinical results.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
[Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Hematuria; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Factors; Umbilicus; Urachal Cyst; Urachus; Urinary Bladder Neoplasms | 2006 |
Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Remission Induction; Urinary Bladder Neoplasms | 2007 |
New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladder.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Genetic Therapy; Humans; Hyperthermia, Induced; Immunotherapy; Medical Oncology; Microwaves; Urinary Bladder Neoplasms; Urology | 2006 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Gemcitabine in bladder cancer.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
[Radiochemotherapeutic options for bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Radiography; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2008 |
Palliative chemotherapy in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Staging; Paclitaxel; Pyrimidines; Trimetrexate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Metastatic bladder cancer: advances in treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Urinary Bladder Neoplasms | 1997 |
New chemotherapy regimens for advanced bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 1998 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 1999 |
Gemcitabine in bladder cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Prognosis; Urinary Bladder Neoplasms | 2000 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine in locally advanced and/or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms; Urothelium | 2000 |
Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2000 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine in the treatment of bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2000 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Gemcitabine in advanced bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Treatment of metastatic urothelial cancer in the post-MVAC era.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscle Neoplasms; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2001 |
Recent developments in chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2001 |
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium; Vinblastine | 2001 |
New chemotherapy combinations for advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Gemcitabine-containing regimens in bladder cancer: A new standard of care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2001 |
Gemcitabine/carboplatin in advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2001 |
Adjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2001 |
[New developments in chemotherapy for metastasized bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Future directions for gemcitabine in the treatment of genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Forecasting; Gemcitabine; Humans; Kidney Neoplasms; Male; Morbidity; Prostatic Neoplasms; Survival Analysis; Testicular Neoplasms; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
163 trial(s) available for deoxycytidine and Bladder Cancer
| Article | Year |
|---|---|
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Methotrexate; Neoadjuvant Therapy; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
Topics: Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms; Vinblastine | 2022 |
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Urinary Bladder Neoplasms | 2022 |
Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Patient Reported Outcome Measures; Platinum; Quality of Life; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoplasm Invasiveness; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2022;82:242-3.
Topics: Antibodies, Monoclonal, Humanized; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms | 2022 |
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Platinum; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Deoxycytidine; Drug Delivery Systems; Female; Humans; Male; Muscles; Urinary Bladder Neoplasms | 2023 |
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Topics: Cisplatin; Cystectomy; Deoxycytidine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2023 |
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Immunotherapy; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms | 2023 |
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Nivolumab; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein | 2023 |
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Urinary Bladder Neoplasms | 2020 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Seconda
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Perioperative Period; Prospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Prognosis; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Neovascularization, Pathologic; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms | 2021 |
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Isoxazoles; Male; Pyrazines; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2018 |
Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Prospective Studies; Radiation Dose Hypofractionation; Urethra; Urinary Bladder Neoplasms | 2018 |
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sodium Chloride; Urinary Bladder Neoplasms; Urothelium | 2018 |
Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Female; Gemcitabine; Humans; Male; Radiation-Sensitizing Agents; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2019 |
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Quality of Life; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2013 |
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Drug Monitoring; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Prospective Studies; Time Factors; Urinary Bladder Neoplasms | 2014 |
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial-an update.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Organ Sparing Treatments; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lymph Node Excision; Male; Methotrexate; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Time Factors; Time-to-Treatment; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Tolerance; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiation Dose Hypofractionation; Radiation Injuries; Radiation Tolerance; Survival Rate; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2017 |
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy; Survival Analysis; Urinary Bladder Neoplasms | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
Intra-arterial chemotherapy with gemcitabine and cisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Postoperative Care; Urinary Bladder Neoplasms | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2010 |
Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Retreatment; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Disease Progression; Endoscopy; Gemcitabine; Humans; Immunotherapy; Recurrence; Reproducibility of Results; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Hydrogen-Ion Concentration; Neoplasm Invasiveness; Tissue Distribution; Urinary Bladder Neoplasms | 2010 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2011 |
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2011 |
[AUO-study AB34/09: an open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Panitumumab; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urothelium | 2011 |
Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gemcitabine; Male; Piroxicam; Urinary Bladder Neoplasms | 2011 |
Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Cystitis; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
[First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Recurrence; Urinary Bladder Neoplasms | 2012 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2012 |
Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2011 |
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GET
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Contraindications; Deoxycytidine; France; Humans; Middle Aged; Organoplatinum Compounds; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2011 |
Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Endoscopy; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Invasiveness; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms; Urine | 2011 |
[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Placebo Effect; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Diseases; Male; Middle Aged; Urinary Bladder Neoplasms | 2012 |
[The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2013 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quality of Life; Radiation-Sensitizing Agents; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Failure; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2003 |
Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Time Factors; Urinary Bladder Neoplasms | 2004 |
Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Urinary Bladder Neoplasms | 2003 |
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2004 |
Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2004 |
Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Surveys and Questionnaires; Thrombocytopenia; Urinary Bladder Neoplasms | 2004 |
Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2004 |
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Function Tests; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Outpatients; Treatment Outcome; Urinary Bladder Neoplasms; Viscera | 2004 |
Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Transitional Cell; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Kidney Function Tests; Life Tables; Male; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2005 |
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prodrugs; Remission Induction; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2005 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2005 |
A nonplatinum combination in metastatic transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms | 2005 |
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder Neoplasms | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2005 |
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Remission Induction; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma in Situ; Chromatography, High Pressure Liquid; Cystoscopy; Deoxycytidine; Disease-Free Survival; Drug Resistance; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms | 2006 |
Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Failure; Urinary Bladder Neoplasms | 2006 |
Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2006 |
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2006 |
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Dose-Response Relationship, Drug; Drug Synergism; Equilibrative Nucleoside Transporter 1; Excitatory Amino Acid Antagonists; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Phosphorylation; Proto-Oncogene Proteins c-akt; S Phase; Thioinosine; Thymidylate Synthase; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Retinoblastoma Protein; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2006 |
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Factors; Urinary Bladder Neoplasms | 2007 |
Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Survival; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy; Urinary Bladder Neoplasms; Urologic Surgical Procedures; Vinblastine | 2006 |
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2007 |
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Turkey; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Male; Neoplasm Metastasis; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2007 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms | 2007 |
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Urinary Bladder Neoplasms | 2007 |
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2007 |
Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Apoptosis; BCG Vaccine; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Technology Transfer; Urinary Bladder Neoplasms | 2007 |
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vitamin B 12; Vitamin B Complex | 2008 |
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neutropenia; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 1994 |
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 1997 |
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 1997 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Thrombocytopenia; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1999 |
Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Diseases; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2000 |
A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Schistosomiasis; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hospitalization; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2001 |
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Topics: Adult; Aged; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Pelvic Neoplasms; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
[Results of phase II clinical trial of cycloplatam in refractory solid tumors].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Pleural Neoplasms; Pleurisy; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2001 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2002 |
415 other study(ies) available for deoxycytidine and Bladder Cancer
| Article | Year |
|---|---|
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; MicroRNAs; Protein-Tyrosine Kinases; RNA, Long Noncoding; Urinary Bladder Neoplasms | 2021 |
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2022 |
Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Berberine; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rad51 Recombinase; Up-Regulation; Urinary Bladder Neoplasms | 2022 |
[A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Muscles; Neoadjuvant Therapy; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Olea; Polyphenols; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Wastewater | 2022 |
microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.
Topics: Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chromosomal Proteins, Non-Histone; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Urinary Bladder Neoplasms | 2022 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; Morpholines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sulfoxides; Urinary Bladder Neoplasms | 2022 |
[Intravesical gemcitabine for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2022 |
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Mycobacterium bovis; Urinary Bladder Neoplasms | 2022 |
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
Topics: Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Gemcitabine; Genomics; Humans; Urinary Bladder Neoplasms | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer.
Topics: Antineoplastic Agents; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Humans; Retrospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Cytokines; Deoxycytidine; Disease Models, Animal; Exosomes; Gemcitabine; Macrophages; Mice; Urinary Bladder Neoplasms | 2022 |
Tumor-targeting albumin nanoparticles as an efficacious drug delivery system and potential diagnostic tool in non-muscle-invasive bladder cancer therapy.
Topics: Albumins; Animals; Deoxycytidine; Drug Delivery Systems; Humans; Mice; Nanoparticles; Urinary Bladder Neoplasms | 2022 |
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Methotrexate; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2023 |
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2022 |
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Prospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2022 |
LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Nanoparticle Drug Delivery System; Polylactic Acid-Polyglycolic Acid Copolymer; Urinary Bladder Neoplasms; Wheat Germ Agglutinins | 2023 |
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2023 |
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2023 |
Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Kidney Transplantation; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome; Urinary Bladder Neoplasms | 2023 |
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2023 |
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Paclitaxel; Urinary Bladder Neoplasms | 2023 |
Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Hungary; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Topics: Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms; Urinary Tract | 2023 |
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Topics: Animals; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunotherapy, Adoptive; Mice; Myeloid-Derived Suppressor Cells; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Neoplasm Recurrence, Local; Principal Component Analysis; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms | 2020 |
Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder Neoplasms | 2020 |
Editorial Comment.
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Health Facilities; Humans; Urinary Bladder Neoplasms | 2020 |
Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Signal Transduction; Thiazoles; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Urothelium; X-Linked Inhibitor of Apoptosis Protein | 2020 |
Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Denmark; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prognosis; Prospective Studies; Quality of Life; Surveys and Questionnaires; Urinary Bladder Neoplasms | 2020 |
Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2020 |
Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Topics: Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Muscles; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Recurrent Bladder Cancer in a Teenage Male.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Deoxycytidine; Gemcitabine; Humans; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Methylation; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Phosphoglycerate Dehydrogenase; Promoter Regions, Genetic; RNA, Messenger; Urinary Bladder Neoplasms | 2020 |
Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Neoplasm Recurrence, Local; Reactive Oxygen Species; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2020 |
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography with Ultraviolet Detection.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Reproducibility of Results; Spectrophotometry, Ultraviolet; Urinary Bladder Neoplasms | 2020 |
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma].
Topics: Adenocarcinoma; Aged; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Urethra; Urethral Neoplasms; Urinary Bladder Neoplasms | 2020 |
Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Creatinine; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Hyponatremia; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Sodium; Urinary Bladder Neoplasms; Urologic Neoplasms | 2020 |
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Gemcitabine; Humans; Mice; Piperazines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2020 |
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comparative Effectiveness Research; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell- and Tissue-Based Therapy; Cisplatin; Deoxycytidine; Epithelial Cells; Gemcitabine; Humans; Immunotherapy; Lymphocyte Activation; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Microspheres; Swine; T-Lymphocytes; Transplantation, Heterologous; Tumor Burden; Urinary Bladder Neoplasms; Urothelium | 2021 |
Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Platelets; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Lymphocytes; Male; Neoplasm Invasiveness; Neutrophils; Platelet Count; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2021 |
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Retreatment; Time Factors; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Decreased drug resistance of bladder cancer using phytochemicals treatment.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Multidrug Resistance-Associated Protein 2; Phytochemicals; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Progression-Free Survival; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medicare; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Social Class; United States; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Topics: Apoptosis; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Microtubule-Associated Proteins; Oncogene Protein v-akt; Phosphorylation; Urinary Bladder Neoplasms | 2021 |
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder].
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Gemcitabine; Humans; Hypersensitivity; Mitomycin; Papilloma, Inverted; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.
Topics: Animals; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Organoids; Urinary Bladder Neoplasms | 2021 |
Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Drug Delivery Systems; Female; Gemcitabine; Mice; Mice, Nude; Microbubbles; Tumor Cells, Cultured; Ultrasonic Therapy; Urinary Bladder Neoplasms | 2021 |
Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model.
Topics: Animals; Antimetabolites, Antineoplastic; Biotinylation; Cell Line, Tumor; Chemoradiotherapy; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Intestines; Mice; Mice, Nude; Microbubbles; Neoplasm Invasiveness; Organs at Risk; Radiation Injuries; Tumor Burden; Ultrasonography; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2021 |
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2021 |
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Internationality; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Topics: Adenoviridae; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Adhesion; Cell Proliferation; Cisplatin; Deoxycytidine; DNA Methylation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Basal Cell; Prognosis; Promoter Regions, Genetic; Proteinase Inhibitory Proteins, Secretory; Retrospective Studies; Survival Rate; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2021 |
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pyrazoles; Pyrimidines; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Chondroitinases and Chondroitin Lyases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Mice; Prognosis; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Delivery of Health Care; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Tapering; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Reported Outcome Measures; Prevalence; Symptom Assessment; Urinary Bladder Neoplasms | 2021 |
Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Models, Biological; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms; Urothelium; Zinc Finger Protein Gli2 | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
BMI1 activates P-glycoprotein via transcription repression of
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; Male; MicroRNAs; Polycomb Repressive Complex 1; Urinary Bladder Neoplasms | 2021 |
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2021 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Male; Middle Aged; Nephrectomy; Neutropenia; Retrospective Studies; Urinary Bladder Neoplasms | 2017 |
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Cytokines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitomycin; Neoplasms, Experimental; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Topics: Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; Urinary Bladder Neoplasms | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2017 |
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase Inhibitor p15; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mutation; Nuclear Proteins; Trans-Activators; Transcription Factors; Tumor Suppressor Protein p53; Up-Regulation; Urinary Bladder Neoplasms | 2018 |
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; HeLa Cells; Humans; Male; MCF-7 Cells; Mutation; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Y-Box-Binding Protein 1 | 2017 |
TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance; Gemcitabine; Humans; Kruppel-Like Factor 4; Male; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Nuclear Factor 90 Proteins; RNA, Long Noncoding; Signal Transduction; Transforming Growth Factor beta1; Urinary Bladder Neoplasms | 2017 |
Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Programmed Cell Death 1 Receptor; Urinary Bladder Neoplasms | 2017 |
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Neoplastic Stem Cells; Phosphoproteins; SOXB1 Transcription Factors; Transcription Factors; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Neoadjuvant Therapy; Noninvasive Ventilation; Prednisolone; Respiratory Insufficiency; Steroids; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Bladder cancer: Chemotherapy and checkpoint blockade.
Topics: Cisplatin; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Ipilimumab; Mutation; Urinary Bladder Neoplasms | 2018 |
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2018 |
The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germany; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Practice Patterns, Physicians'; Surveys and Questionnaires; Urinary Bladder Neoplasms; Urology | 2018 |
Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation.
Topics: Aged; Aged, 80 and over; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Membrane Proteins; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Hypoxia; Urinary Bladder Neoplasms | 2018 |
Gemcitabine reduces recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2018 |
Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience."
Topics: BCG Vaccine; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Retrospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2018 |
Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Gemcitabine; Humans; In Vitro Techniques; Microscopy, Electron, Scanning; Microspheres; Neoplasms, Experimental; Particle Size; Rats; Rats, Sprague-Dawley; Rheology; Urinary Bladder Neoplasms; Viscosity | 2018 |
A gel system for single instillation of non-muscle-invasive bladder Cancer: A "divide-and-rule" strategy.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Dendrimers; Deoxycytidine; Dextrans; Doxorubicin; Drug Delivery Systems; Female; Gels; Gemcitabine; Mice; Mice, Inbred BALB C; Mice, Nude; Polyethylene Glycols; Urinary Bladder Neoplasms | 2018 |
miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Male; MicroRNAs; Middle Aged; Urinary Bladder Neoplasms; Wnt-5a Protein | 2018 |
Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Synergism; Epoxy Compounds; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Glycogen Synthase Kinase 3 beta; Humans; Phenanthrenes; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Topics: Acetylglucosamine; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; N-Acetylglucosaminyltransferases; Urinary Bladder Neoplasms | 2018 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Young Adult | 2018 |
Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; MicroRNAs; Protein Interaction Maps; RNA, Messenger; Small Molecule Libraries; Urinary Bladder Neoplasms | 2019 |
Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pelvis; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasms, Multiple Primary; Survival Rate; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-Arrestin 1; beta-Arrestin 2; Cell Line, Tumor; Cisplatin; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Phenotype; Prognosis; Stem Cells; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2019 |
Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Decitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Neoplastic Stem Cells; Urinary Bladder Neoplasms | 2019 |
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
Topics: Animals; Benzoxazines; Cell Line, Tumor; Chemokine CCL2; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Middle Aged; Monocytes; Myeloid-Derived Suppressor Cells; Spiro Compounds; Survival Analysis; T-Lymphocytes; Tumor Microenvironment; Urinary Bladder Neoplasms | 2019 |
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Long Noncoding; Up-Regulation; Urinary Bladder Neoplasms | 2019 |
Chemotherapy Toxicity Confirms Diagnosis of Urachal Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystoscopy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Image-Guided Biopsy; Leucovorin; Male; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2019 |
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Predictive Value of Tests; Random Allocation; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder Neoplasms | 2019 |
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Topics: Animals; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Margins of Excision; Mice; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Random Allocation; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Recurrence; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Perioperative chemotherapy: when to use it, what to use, and why.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2013 |
New agents for bacillus Calmette-Guérin-refractory bladder cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Lectins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2013 |
Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Acute generalized exanthematous pustulosis caused by gemcitabine.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2014 |
Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen).
Topics: Adult; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Biomimetic Materials; Cell Adhesion; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Gemcitabine; Humans; Lactic Acid; Mitomycin; Phosphatidylcholines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Stearic Acids; Urinary Bladder Neoplasms; Urothelium; Wheat Germ Agglutinins | 2013 |
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Risk Assessment; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
[Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Genes, bcl-2; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Mice, Nude; Mitochondrial Proteins; Molecular Mimicry; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2013 |
[Metastatic micropapillary variant of urothelial carcinoma of the urinary bladder responding to gemcitabine and cisplatin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Smoking; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Nucleoside Transport Proteins; Platinum Compounds; Predictive Value of Tests; Urinary Bladder Neoplasms | 2014 |
Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Choroidal Neovascularization; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Fluorescein Angiography; Gemcitabine; Humans; Male; Remission Induction; Taxoids; Tomography, Optical Coherence; Urethral Neoplasms; Urinary Bladder Neoplasms | 2013 |
A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen).
Topics: Age Factors; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunoblotting; Microscopy, Fluorescence; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2014 |
[Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Topics: Adenoviridae; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Galactosides; Gemcitabine; Indoles; Mice; Mice, Nude; Models, Animal; Urinary Bladder Neoplasms | 2013 |
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Perioperative Period; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Gemcitabine; Humans; Light; Mitomycin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Time Factors; Urinary Bladder Neoplasms | 2014 |
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolinones; Random Allocation; Receptor, ErbB-2; Receptor, ErbB-4; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Feasibility of pre- and postoperative gemcitabine-plus-cisplatin systemic chemotherapy for the treatment of locally advanced urothelial carcinoma in kidney transplant patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Kidney Transplantation; Male; Middle Aged; Urinary Bladder Neoplasms | 2013 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
[Non-muscle invasive bladder cancer with multiple bone metastasis without local invasion : a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2013 |
No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Comet Assay; Deoxycytidine; DNA Damage; DNA Methylation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MutL Protein Homolog 1; Nuclear Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Fragmentation; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Securin; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Urothelium | 2014 |
Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organ Sparing Treatments; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Topics: 4-Quinolones; Aniline Compounds; Animals; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, Nude; Nanoparticles; NIH 3T3 Cells; Urinary Bladder Neoplasms | 2014 |
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2014 |
Efficacy of radical cystectomy plus adjuvant intraarterial chemotherapy with gemcitabine and cisplatin on locally advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Renal Dialysis; Urinary Bladder Neoplasms | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2014 |
Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Gemcitabine; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Pyridines; Urinary Bladder Neoplasms | 2014 |
[Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Bone metastases from bladder perivascular epithelioid cell tumor - an unusual localization of a rare tumor: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Ilium; Male; Perivascular Epithelioid Cell Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2014 |
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Quality of Life; Retrospective Studies; Survival Rate; United States; Urinary Bladder Neoplasms | 2014 |
Novel bladder preservation therapy with Osaka Medical College regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Radiotherapy, Adjuvant; Renal Dialysis; Survival Rate; Urinary Bladder Neoplasms | 2015 |
Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Male; Methotrexate; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; RNA, Messenger; RNA, Small Interfering; Urinary Bladder Neoplasms | 2014 |
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Europe; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; North America; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mutation; Protein Kinases; Pyrazoles; Thiophenes; Tumor Suppressor Protein p53; Urea; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Perioperative Care; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2015 |
The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Slovakia; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2014 |
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice.
Topics: Antineoplastic Agents; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Health Surveys; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2015 |
Commentary on "The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial." Gontero P, O
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Female; Humans; Male; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2015 |
Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Patient Selection; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2015 |
Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2015 |
Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Kidney Transplantation; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
[Management of metastatic bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2014 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
[Intravesical gemcitabine for non-muscle invasive bladder cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Humans; Urinary Bladder Neoplasms | 2015 |
Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2015 |
Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Humans; Male; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2015 |
Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression; Humans; Kidney Neoplasms; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Urinary Bladder Neoplasms | 2015 |
δ-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Vitamin E | 2015 |
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gossypol; Humans; Membrane Proteins; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Urinary Bladder Neoplasms | 2015 |
Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Cell Death; Cell Line, Tumor; Deoxycytidine; Endocytosis; Female; Fluorescence; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neurotensin; Protein Binding; Urinary Bladder Neoplasms | 2015 |
Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Risk Assessment; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Carotid artery inflammation associated with gemcitabine-based therapy: a special report.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteritis; Carotid Arteries; Carotid Artery Diseases; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Vasculitis | 2015 |
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; RNA, Messenger; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carboplatin; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lymphatic Metastasis; Lymphatic Vessels; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Deoxycytidine; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor beta; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Tamoxifen; Urinary Bladder Neoplasms | 2015 |
Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulins, Intravenous; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiography; Urinary Bladder Neoplasms; von Willebrand Disease, Type 2 | 2016 |
Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Topics: Animals; Apoptosis; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Thalidomide; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Chitosan; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Design; Gels; Gemcitabine; Humans; Nanoparticles; Poloxamer; Thioglycolates; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2015 |
[The Combination Therapy of Gemcitabine Plus Paclitaxel Induced Complete Response in a Tongue Skin Brain Metastasis of Bladder Carcinoma: A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Skin Neoplasms; Tongue Neoplasms; Urinary Bladder Neoplasms | 2015 |
Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Topics: Aged; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Male; Proto-Oncogene Proteins c-akt; Repressor Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Kidney Neoplasms; Kidney Pelvis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Retrospective Studies; Stroke; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Venous Thromboembolism | 2016 |
Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2016 |
A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cluster Analysis; Cysteine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kinesins; Mice, Inbred BALB C; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA Interference; Trityl Compounds; Tumor Burden; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Transitional Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Male; Middle Aged; Mitomycin; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Cells, Cultured; Ubiquitin-Activating Enzymes; Urinary Bladder Neoplasms; Young Adult | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Singapore; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Glutathione; Humans; Mass Spectrometry; Methotrexate; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2016 |
Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Transplantation; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2016 |
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Organs at Risk; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
A Case of Severe Rectal Hemorrhage Possibly Caused by Radiation Recall after Administration of Gemcitabine.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gamma Rays; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Radiation-Sensitizing Agents; Radiodermatitis; Rectum; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2016 |
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Topics: Animals; Cell Differentiation; Cell Line; Cell Line, Tumor; Cisplatin; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred NOD; Mice, SCID; Protein Isoforms; RNA, Small Interfering; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Sarcomatoid Carcinoma of the Bladder in a Child: Case Report of a Successful Treatment Including Gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Organ Sparing Treatments; Radiotherapy, Adjuvant; Urinary Bladder Neoplasms | 2016 |
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Autophagy; Beclin-1; Capsaicin; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Hedgehog Proteins; Homeostasis; Humans; Mitomycin; Oxidation-Reduction; Oxidative Stress; Patched-2 Receptor; Phenotype; Reactive Oxygen Species; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Deubiquitinating Enzyme CYLD; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; France; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2017 |
Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Promoter Regions, Genetic; RNA Interference; RNA, Long Noncoding; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Topics: Administration, Intravesical; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Drug Interactions; Enoxaparin; Gemcitabine; Humans; International Normalized Ratio; Male; Urinary Bladder Neoplasms; Venous Thrombosis; Warfarin | 2016 |
Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Statistics as Topic; Urinary Bladder Neoplasms | 2016 |
Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Neoplasm Metastasis; Prospective Studies; Serum Albumin; Survival Rate; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Withholding Treatment | 2017 |
A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Models, Biological; Urinary Bladder Neoplasms | 2017 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
Topics: Androgens; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Urinary Bladder Neoplasms | 2017 |
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms; Venous Thromboembolism | 2017 |
A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neutropenia; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; RNA, Small Interfering; Thiophenes; Urea; Urinary Bladder Neoplasms | 2017 |
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Databases, Factual; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2017 |
Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2017 |
The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glycosides; Humans; Sea Cucumbers; Triterpenes; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2017 |
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Introns; Logistic Models; Male; Middle Aged; Models, Genetic; N-Acetylgalactosaminyltransferases; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Polypeptide N-acetylgalactosaminyltransferase; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2017 |
Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2017 |
Gemcitabine-induced retinopathy in a diabetic patient.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diabetes Mellitus, Type 1; Fluorescein Angiography; Gemcitabine; Humans; Male; Middle Aged; Retinal Neovascularization; Urinary Bladder Neoplasms; Visual Acuity | 2009 |
Neoadjuvant gemcitabine and cisplatin: another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2008 |
Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Metastasis; Oligonucleotides, Antisense; Thionucleotides; Urinary Bladder Neoplasms | 2009 |
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Feasibility Studies; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Universities; Urinary Bladder Neoplasms; Vinblastine | 2009 |
[Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Gemcitabine; Humans; Lymphatic Metastasis; Male; Urinary Bladder Neoplasms | 2008 |
[Metastases from urethelial carcinoma: role of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2008 |
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Selection; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Gemcitabine induced digital ischaemia and necrosis.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Fingers; Gemcitabine; Humans; Iloprost; Ischemia; Magnetic Resonance Angiography; Necrosis; Urinary Bladder Neoplasms; Vasodilator Agents | 2010 |
Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2.
Topics: Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Thymidine Kinase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; DNA Primers; Drug Synergism; Gemcitabine; Humans; Models, Biological; Neovascularization, Pathologic; Urinary Bladder Neoplasms | 2010 |
Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
Topics: Absorption; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urethra; Urinary Bladder Neoplasms | 2009 |
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2009 |
Editorial comment.
Topics: Absorption; Administration, Intravesical; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Urethra; Urinary Bladder Neoplasms | 2009 |
Drug compendia in oncology: are they flawed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Conflict of Interest; Deoxycytidine; Gemcitabine; Humans; Medicaid; Medical Oncology; Medicare; Pharmacopoeias as Topic; United States; Urinary Bladder Neoplasms | 2009 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
[Cerebral vasculitis associated with gemcitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cerebral Cortex; Cisplatin; Cognition Disorders; Deoxycytidine; Epilepsy, Tonic-Clonic; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Urinary Bladder Neoplasms; Vasculitis, Central Nervous System | 2010 |
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2010 |
Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Posterior Leukoencephalopathy Syndrome; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2010 |
Bladder cancer: can we move beyond chemotherapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Urinary Bladder Neoplasms | 2010 |
Haemolytic uraemic syndrome associated with gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Urinary Bladder Neoplasms; Urothelium | 2010 |
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Urinary Bladder Neoplasms | 2010 |
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcitriol; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Nuclear Proteins; Receptors, Calcitriol; Tumor Protein p73; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Vitamin D; Xenograft Model Antitumor Assays | 2010 |
Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytoprotection; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heme Oxygenase-1; Humans; Mice; Mice, Inbred BALB C; Protoporphyrins; Radiation Tolerance; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2010 |
The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Particle Accelerators; Prognosis; Proportional Hazards Models; Prospective Studies; Radiotherapy Dosage; Retrospective Studies; Time Factors; Urinary Bladder Neoplasms; Young Adult | 2010 |
Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Radiotherapy, Adjuvant; Renal Dialysis; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Induction chemotherapy for unresectable urothelial carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Epidemiologic Methods; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2011 |
Conditions causing gemcitabine crystallization.
Topics: Administration, Intravesical; Chromatography, High Pressure Liquid; Cold Temperature; Crystallization; Deoxycytidine; Drug Storage; Gemcitabine; Hydrogen-Ion Concentration; Urinary Bladder Neoplasms | 2011 |
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Citrates; Deoxycytidine; Energy Metabolism; Female; Gemcitabine; Humans; Methotrexate; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Retrospective Studies; Urinary Bladder Neoplasms | 2010 |
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2010 |
Microemulsions for intravesical delivery of gemcitabine.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Emulsions; Female; Gemcitabine; Humans; Rats; Rats, Sprague-Dawley; Urinary Bladder; Urinary Bladder Neoplasms | 2010 |
Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; BCG Vaccine; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Ki-67 Antigen; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Urinary Bladder Neoplasms | 2010 |
Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Neoplasm Staging; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2010 |
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Impact of adjuvant chemotherapy on patients with lymph node metastasis at the time of radical cystectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Multivariate Analysis; Regression Analysis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms; Vinblastine | 2010 |
Pulmonary cryptococcus infection after mono-chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cryptococcosis; Cryptococcus neoformans; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Fungal; Male; Urinary Bladder Neoplasms | 2011 |
Chronic thrombotic microangiopathy secondary to chemotherapy for urothelial carcinoma in a patient with a history of Wegener granulomatosis.
Topics: Antimetabolites, Antineoplastic; Chronic Disease; Deoxycytidine; Gemcitabine; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged; Thrombotic Microangiopathies; Urinary Bladder Neoplasms | 2011 |
UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Chromones; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Screening Assays, Antitumor; Elafin; Formazans; Gemcitabine; Gene Expression Regulation; Gene Silencing; Humans; Morpholines; RNA, Small Interfering; Spectrometry, Mass, Electrospray Ionization; Tetrazolium Salts; Ubiquitins; Urinary Bladder Neoplasms | 2011 |
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Cisplatin; COS Cells; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplasm Staging; Protein Isoforms; Survival Analysis; Transcription Factor AP-2; Urinary Bladder Neoplasms | 2011 |
Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL.
Topics: Apoptosis; Carcinoma, Transitional Cell; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms | 2011 |
[The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms | 2011 |
Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Deoxycytidine; Gemcitabine; Male; Mice; Mice, Inbred ICR; Neoplasm Invasiveness; Sirolimus; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle Neoplasms; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Urinary Bladder Neoplasms | 2012 |
Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Urinary Bladder Neoplasms | 2012 |
Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pelvic Neoplasms; Urinary Bladder Neoplasms | 2011 |
Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms | 2011 |
High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Urinary Bladder Neoplasms; Urothelium | 2011 |
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Chondroitin Sulfates; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2012 |
Re: gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Topics: Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Humans; Male; Urinary Bladder Neoplasms | 2011 |
Development of thrombotic microangiopathy in a patient with granulomatosis with polyangiitis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Granulomatosis with Polyangiitis; Humans; Male; Thrombotic Microangiopathies; Urinary Bladder Neoplasms | 2011 |
[Experience with gemcitabine monotherapy in three patients with metastatic urothelial carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2011 |
Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Drug Evaluation; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Aldo-Keto Reductases; Carboplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Urinary Bladder Neoplasms | 2013 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
[A case of a patient with bladder cancer who received warfarin and showed a significantly prolonged PT-INR after gemcitabine and cisplatin combination therapy].
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Edema; Female; Gemcitabine; Humans; International Normalized Ratio; Leg; Prothrombin; Thrombophlebitis; Urinary Bladder Neoplasms; Warfarin | 2012 |
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Cystectomy; Cystoscopy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Rate; Urinary Bladder Neoplasms | 2012 |
Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gemcitabine; Humans; Mutagens; Neoplasm Invasiveness; Osmolar Concentration; S Phase; Sirolimus; Urinary Bladder Neoplasms | 2012 |
Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C-Reactive Protein; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Urinary Bladder Neoplasms | 2012 |
Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
[A case of renal salt wasting syndrome progressing to severe hyponatremia after gemcitabine-cisplatin chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Diseases; Male; Sodium; Urinary Bladder Neoplasms | 2012 |
Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Transcriptome; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2012 |
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vomiting | 2013 |
[A case of advanced rectal cancer with bladder carcinoma salvaged from myocardial infarction during operation, showing tumor regression by XELOX treatment, good quality of life].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Intraoperative Complications; Male; Myocardial Infarction; Neoplasms, Multiple Primary; Oxaloacetates; Quality of Life; Rectal Neoplasms; Salvage Therapy; Urinary Bladder Neoplasms | 2013 |
Early detection and gemcitabine/cisplatin combination positively effect survival in sarcomatoid carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Early Diagnosis; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2013 |
Intravesical therapy for superficial cancer: need for more options.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2002 |
Selective cytotoxicity of gemcitabine in bladder cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Coculture Techniques; Coloring Agents; Deoxycytidine; Fibroblasts; Gemcitabine; Humans; Immunohistochemistry; Rats; Spheroids, Cellular; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Extensive cutaneous metastasis of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Staging; Severity of Illness Index; Skin Neoplasms; Treatment Refusal; Urinary Bladder Neoplasms | 2003 |
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Flow Cytometry; Gemcitabine; Genes, p53; Humans; In Situ Nick-End Labeling; Mutation; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Urinary Bladder Neoplasms | 2003 |
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2003 |
Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Swine; Urinary Bladder; Urinary Bladder Neoplasms | 2003 |
Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fingers; Gangrene; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Iloprost; Male; Middle Aged; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Vasodilator Agents | 2003 |
Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Stevens-Johnson Syndrome; Urinary Bladder Neoplasms | 2003 |
[Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms | 2003 |
Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Survival; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2003 |
[A case of undifferentiated bladder carcinoma with axilla lymph node metastasis successfully treated with gemcitabine and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Urinary Bladder Neoplasms | 2003 |
An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Colony-Forming Units Assay; Deoxycytidine; Gemcitabine; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Urinary Diversion; Vasculitis | 2004 |
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Clinical Trials as Topic; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Mutation; Rhodamines; Time Factors; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2004 |
Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2004 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clusterin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Molecular Chaperones; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Urinary Bladder Neoplasms | 2004 |
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; DNA, Complementary; Fluorine; Fluorouracil; Humans; Immunohistochemistry; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Phantoms, Imaging; Temperature; Thymidine Phosphorylase; Time Factors; Urinary Bladder Neoplasms | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Esophageal Neoplasms; Gemcitabine; Gene Expression Profiling; Humans; Light; Phosphorylation; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Transplantation, Heterologous; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Severe neurotoxicity caused by gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Diseases; Confusion; Deoxycytidine; Female; Gemcitabine; Headache; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Seizures; Urinary Bladder Neoplasms | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cyclohexanes; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cystitis; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fibrosis; Gemcitabine; Hyperplasia; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Organ Size; Single-Blind Method; Urinary Bladder Neoplasms; Urothelium | 2004 |
[Hypertrophic myopathy due to muscular metastasis of a signet cell adenocarcinoma of the bladder].
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Deoxycytidine; Gemcitabine; Humans; Hypertrophy; Male; Muscle Neoplasms; Muscle, Skeletal; Muscular Diseases; Neoplasm Recurrence, Local; Thigh; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[Initial results of intra-arterial chemotherapy for poorly differentiated bladder transitional cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Urinary Bladder Neoplasms | 2004 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Energy Intake; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Taxoids; Tissue Polypeptide Antigen; Urinary Bladder Neoplasms | 2004 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Hyperthermia, Induced; Indolequinones; Mitomycin; Tetrazolium Salts; Thiazoles; Urinary Bladder Neoplasms | 2005 |
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Patient Satisfaction; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitomycin; Oligonucleotides, Antisense; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2005 |
A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prodrugs; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2005 |
Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Neoplasm Seeding; Neoplasm Transplantation; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms | 2005 |
[Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy; Urinary Bladder Neoplasms | 2005 |
Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Inflammation; Keratinocytes; Male; Photosensitivity Disorders; Phototherapy; Ultraviolet Rays; Urinary Bladder Neoplasms | 2005 |
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Urinary Bladder Neoplasms | 2005 |
What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Approval; Gemcitabine; Humans; National Health Programs; New Zealand; Urinary Bladder Neoplasms | 2005 |
PHARMAC's response on gemcitabine and transparency.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Approval; Gemcitabine; Humans; National Health Programs; New Zealand; Urinary Bladder Neoplasms | 2005 |
Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prognosis; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2006 |
Vitamin D receptor agonists, cancer and the immune system: an intricate relationship.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Synergism; Epirubicin; Gemcitabine; Humans; Molecular Structure; Receptors, Calcitriol; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2006 |
Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Retroperitoneal Neoplasms; Ribonucleotide Reductases; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2006 |
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Vitamins C and K3 sensitize human urothelial tumors to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Ascorbic Acid; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Urinary Bladder Neoplasms; Urothelium; Vitamin K 3; Vitamins | 2006 |
Haematological toxicity in patients treated with cisplatin and gemcitabine for bladder cancer: the Weston Park Hospital, Sheffield, experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carcinoma, Transitional Cell; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Gemcitabine; Humans; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Urinary Bladder Neoplasms | 2007 |
[A case of small cell carcinoma in the urinary bladder responding to gemcitabine/cisplatin combination therapy as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Urinary Bladder Neoplasms; Urinary Diversion | 2006 |
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Caveolin 1; Cisplatin; Databases as Topic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2007 |
Prediction of drug combination chemosensitivity in human bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Predictive Value of Tests; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.
Topics: Antineoplastic Agents; Brain Diseases; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms | 2007 |
Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cell
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Membrane Proteins; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerases; Smoking; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.1].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Agmatine; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Gemcitabine; Humans; Male; Mitomycin; Succinates; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Moving forward in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; ErbB Receptors; Gemcitabine; Humans; Methotrexate; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchiolitis Obliterans; Carboplatin; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Hypoxia; Male; Pneumonia; Urinary Bladder Neoplasms | 2007 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Transitional Cell; Colonic Pouches; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Rectal Neoplasms; Urinary Bladder Neoplasms | 2007 |
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms | 2007 |
Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Re: The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Topics: Administration, Intravesical; Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2008 |
Ureterovesical malignancy following renal transplantation: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Incidence; Kidney Transplantation; Male; Peritoneal Dialysis, Continuous Ambulatory; Radiography; Time Factors; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2007 |
[Favorable outcome of gemcitabine-induced acute respiratory distress syndrome].
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Respiratory Distress Syndrome; Urinary Bladder Neoplasms | 2007 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
[Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal Outcome; Floxuridine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2008 |
[Elevation of CA 19.9 in urothelial bladder cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
[Oncology--a common language, new perspectives. Lilly Oncology Global Medical Conference, Indianapolis, 1996].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Medical Oncology; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 1996 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2001 |
Bladder tumor markers, intravesical therapy and systemic chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Death; Cell Line; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunohistochemistry; Mutation; Paclitaxel; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2001 |
Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Remission Induction; Urinary Bladder Neoplasms | 2001 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2002 |